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ABSTRACT OF DISSERTATION 
 
 
MECHANISMS OF CYCLOOXYGENASE-2-DEPENDENT HUMAN 
AORTIC SMOOTH MUSCLE CELL PHENOTYPIC MODULATION 
Abdominal aortic aneurysm (AAA) is a disease of the aorta characterized 
by pathological remodeling and progressive weakening of the vessel resulting in 
the increased risk of rupture and sudden death. In a mouse model of the disease 
induced by chronic Angiotensin II (AngII) infusion, progression of AAAs is 
associated with reduced differentiation of smooth muscle cells (SMCs) at the site 
of lesion development. In the mouse model, the effectiveness of cyclooxygenase-
2 (COX-2) inhibition for attenuating AAA progression is associated with 
maintenance of a differentiated SMC phenotype. However, the safety of COX-2 
inhibitors is currently in question due to the increased risk of adverse 
cardiovascular events. Thus, it is crucial to identify mediators downstream of 
COX-2 that may provide new targets for treatment of this disease. 
Recent studies in humans and mouse models have suggested that the 
microsomal prostaglandin E synthase (mPGES-1) enzyme, which acts 
downstream of COX-2, may also be involved in the pathogenesis of the disease. 
We hypothesized that increased prostaglandin E2 (PGE2) synthesis resulting 
from the induction of both COX-2 and mPGES-1 may result in reduced 
differentiation of SMCs, and that disruption of this pathway would preserve the 
differentiated phenotype. To test this hypothesis, human aortic smooth muscle 
cells (hASMCs) were utilized to examine the effects of a variety of agents 
involved in AAA development and the COX-2 pathway.  
My findings suggest that one of the effects of exposing hASMCs to AngII 
involves a specific induction of mPGES-1 expression. Furthermore, although 
different COX-2-derived products may have opposing effects, mPGES-1-derived 
PGE2 may be the primary prostanoid synthesized by SMCs which functions to 
attenuate differentiation. Therefore, mPGES-1 inhibition may provide inhibition of 
 PGE2 that is more specific than COX-2 inhibitor treatment and may serve as a 
therapeutic target for attenuating AAA progression by maintaining a differentiated 
SMC phenotype. 
 
KEYWORDS: vascular smooth muscle cell phenotype, abdominal aortic 
aneurysm, Angiotensin II, prostaglandin E2, microsomal prostaglandin E synthase 
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CHAPTER 1: INTRODUCTION 
1.0 Physiology of mammalian blood vessels 
During embryogenesis, blood vessels are among the first organs to 
develop as these vessels are important for further organogenesis as well as for 
sufficient nutrition of the embryo [1]. Mature blood vessels are comprised of three 
distinct layers: the tunica intima, tunica media, and tunica adventitia. The tunica 
intima is composed of endothelial cells lying on a basement membrane of type IV 
collagen, laminin and heparin sulfate proteoglycans. Between the intima and the 
media is a layer of internal elastic lamina composed of mainly elastin and 
hyaluronic acid. The tunica media is primarily composed of elastic fibers and 
smooth muscle cells (SMCs) arranged circumferentially. The adventitia, which is 
the outermost layer, consists mainly of collagen fibers, loose connective tissue, 
fibroblasts, and fat cells, with an external elastic lamina separating this layer from 
the outer media [2].   
 
1.1 Phenotypic modulation of VSMCs  
The SMCs are responsible for maintaining artery wall tension via 
contraction-relaxation, vascular remodeling, repair, as well as growth [2-6]. 
Normal smooth muscle cells have a distinct smooth appearance and the 
differentiated phenotype is specifically marked by the expression of SMC lineage 
markers and the acquisition of contractile function [7]. Cell differentiation involves 
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transition from an initial multipotential state to a specialized form thus assuming a 
different morphology as well as function [6].  
Phenotypic modulation is a unique characteristic of vascular SMCs which 
is demonstrated by their ability to switch their phenotype between the contractile 
(differentiated) and synthetic (de-differentiated) phenotypes in response to 
various environmental/external cues such as growth factors/inhibitors, 
inflammatory mediators, cytokines, and matrix metalloproteinases [8-18]. This 
characteristic property of vascular SMCs is important in regulation of vascular 
function in health and disease [19]. The contractile and synthetic phenotypic 
states are two extremes of the spectrum of SMC phenotypic expression and cells 
expressing features of both phenotypes have been identified [20]. Furthermore, 
vascular SMCs do not de-differentiate terminally but retain sufficient plasticity to 
change back and forth between the differentiated and de-differentiated 
phenotypes [21]. A variety of transcription factors including myocardin, myocardin 
related transcription factors (MRTFs), and members of the Krüppel-like zinc 
finger family (KLF) have been suggested to act as molecular switches involved in 
the regulation of vascular SMC differentiation [22]. Increased binding of the 
serum response factor (SRF) and its coactivator myocardin and then to the CArG 
motif of differentiation marker genes, induces transcription and increased 
expression of these differentiation markers [23]. 
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1.1.1 The contractile differentiated phenotype  
The differentiated/contractile phenotype is demonstrated by expression of 
several SMC contractile proteins that are used as differentiation markers (e.g. 
smooth muscle α-actin, SMC myosin heavy chain, β-tropomyosin, desmin, h-
caldesmon, calponin, smoothelin, and SM22α) which are involved in 
maintenance and regulation of contractile function [7, 12, 24-29]. Cells in this 
phenotype contract in response to chemical and mechanical stimuli and thus 
function in regulating blood pressure and flow [26].  
 
1.1.2 The synthetic de-differentiated phenotype 
Cells in the de-differentiated or synthetic phenotype downregulate the 
expression of differentiation markers and express high levels of synthetic 
phenotype markers (e.g. hyaluronic acid, MMP-2, l-caldesmon, vimentin, and 
non-muscle myosin heavy chain B). Furthermore, these de-differentiated cells 
exhibit large, rhomboid, flattened, fibroblast-like morphology, and demonstrate an 
increase in proliferative and migration rates compared with the contractile 
phenotype [12, 15, 16, 26, 28, 30-34]. Previously, the proliferation and 
differentiation processes were assumed to be coupled, with reduction in 
differentiation being a prerequisite for proliferation. However, these processes 
are now understood to be independent wherein growth factors may induce 
proliferation independent of reduced differentiation marker expression and vice-
versa [35].  
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1.2 Micro RNAs and the vascular SMC phenotype 
Micro RNAs (miRs) are endogenous, small single-stranded, non-coding RNAs 
about 22 nucleotides in length which base pair with the 3’-untranslated region 
(UTR) of target RNAs thereby modulating gene expression and protein synthesis 
[36, 37]. Depending on the degree of complementarity between a mature mRNA 
and its target mRNA UTR, microRNAs may regulate gene expression by 
mediating translational repression, activation or degradation of the target mRNA 
[37]. In vascular SMCs, a variety of miRNAs have been reported to regulate the 
phenotype of these cells in response to vascular injury thus indicating that 
manipulation of these targets/mediators may be utilized as potential new 
therapeutic targets [36]. 
Numerous reports have indicated that miR-145 which is the most abundant 
miR in normal vascular walls, has been demonstrated to regulate the phenotype 
of vascular SMCs. miR-145 is expressed in a gene cluster with miR-143 and 
deficiency of this cluster in mice has been demonstrated to result in the reduced 
abiity of miR-143/145-deficient mice to acquire the contractile phenotype due to 
their accumulation of synthetic vascular SMCs and specific defects in GPCR 
receptor-mediated signaling [38]. Overexpression of these miRs in a rat model of 
acute vascular injury was demonstrated to decrease neointimal formation while 
loss of this cluster resulted in altered differentiation of the SMCs and structural 
modification of the aorta [39]. Furthermore, miR-145 has been identified as a 
phenotypic marker for the differentiated phenotype in cultured vascular SMCs 
and it also induces expression of vascular SMC differentiation marker genes [40]. 
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In addition, the miR143/145 cluster has been demonstrated to promote 
differentiation and repress proliferation in vascular SMCs by inhibiting 
suppressors of myocardin/serum response factor activity such as Kruppel-like 
factor 4 (KL4), and ELK1 (member of ETS oncogene family) [22, 41]. 
Other miRs apart from the miR143/145 cluster have been involved in the 
regulation of the vascular SMC phenotype. Recent research has identified miR-
663 as a novel regulator of phenotypic switch and function in human aortic 
vascular SMCs. Overexpression of this miR promotes the contractile phenotype 
and suppresses formation of neointimal lesions in a mouse model of vascular 
injury by suppression of JUNB expression [42]. Furthermore, increased 
expression of miR-21 induced by TGFβ and BMP signaling mediates the 
induction of the contractile phenotype in vascular SMCs [43]. On the other hand, 
miR-31 has been shown to bind to its target gene cellular repressor of E1A-
stimulated genes (CREG), thus negatively regulating vascular SMC phenotypic 
modulation by repressing expression of SMC differentiation markers [44]. 
Similarly, miR-221 which is upregulated by PDGF, reduces the expression of 
vascular SMC differentiation markers by inhibition of c-Kit, which is a positive 
regulator of myocardin expression [36, 45]. 
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1.3 Phenotypic modulation of VSMCs in the development of vascular 
disease 
Modulation of the vascular SMC phenotype plays a key role in contribution 
to vascular pathology. The pathogenesis of most cardiovascular diseases usually 
involves dysfunction of the vascular smooth muscle cells of the tunica media. 
Fully differentiated vascular SMCs proliferate extremely slowly while expressing 
low levels of extracellular matrix proteins. However, these processes are 
reversed and in fact accelerated during vessel remodeling following vessel injury 
or atherogenesis [46]. In certain vascular disorders such as atherosclerosis [47-
49], restenosis due to vascular injury [9, 50-52], hypertension, and abdominal 
aortic aneurysms, the decrease in protein and mRNA expression of SMC 
differentiation markers has been observed within the vascular wall [46, 53]. Also, 
increased expression of de-differentiation markers by SMCs has been associated 
with these diseases [15, 31, 53-61].  
In in vitro vascular SMC culture models, the synthetic phenotype shows 
changes in SMC morphology from large, flattened, fibroblast-like morphology 
with increased SMC proliferative and migration rates, as compared to the 
elongated, spindle-shape in the contractile phenotype [12, 15, 16, 26, 28, 30-33] 
[34]. The identification of novel pathways altered during the progression of 
vascular SMC phenotype modulation is important in the identification of 
mechanisms contributing to cardiovascular disease.  
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1.3.1 Atherosclerosis 
Atherosclerosis which has been recognized as the leading cause of death 
in the developed world, is a common vascular disorder characterized by arterial 
hardening due to deposition of lipids, cholesterol and other substances within the 
arterial walls forming plaques [62]. Rupture of these plaques may result in 
thrombus formation and vessel occlusion, thus resulting in a myriad of 
cardiovascular diseases including coronary, cerebrovascular and peripheral 
artery disease [63]. During progression of atherosclerosis, the resulting 
endothelial dysfunction due to a combination of changes in shear stress, oxidized 
LDL and inflammatory cytokines, results in the increased expression of 
endothelial adhesion molecules and loss of endothelium-derived factors such as 
prostacyclin and nitric oxide [33, 63-65]. Furthermore, inflammatory cells that 
have infiltrated into the vessel wall release mediators including growth factors 
and cytokines that produce SMC phenotypic changes from the contractile to the 
synthetic state resulting in increased migratory ability and deposition of 
extracellular matrix (ECM) [62]. As the SMCs migrate into the intima, they 
release proinflammatory factors that contribute to atherosclerotic lesion formation 
[19]. These atherosclerotic lesions are characterized by the accumulation of 
layers of de-differentiated SMCs, as well as lipid-filled macrophages [25]. Thus, 
alteration of the vascular SMC phenotype affects the ability of the lesion to 
respond to different agonists [66]. Recently, Yu et al (2012) reported vascular 
SMC phenotypic modulation with acceleration of atherogenesis in COX-2 deleted 
hyperlipidemic ApoE-deficient mice. This was demonstrated by the loss of SMC 
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α-actin and upregulation of vascular cell adhesion molecule-1 (VCAM-1) in the 
leukocyte infiltrated lesions [67]. 
 
1.3.2 Restenosis due to vascular injury 
De-differentiation of vascular SMCs is often observed in the vessel wall 
during progression of restenosis following to vascular wall injury caused by 
percutaneous transluminal coronary angioplasty [9, 50-52]. Restenosis is an 
initial repair process induced following vessel wall injury that occurs in response 
to endothelial denudation or direct vascular trauma produced by the intravascular 
procedure [52]. These de-differentiated cells subsequently migrate into the 
subintimal space and increase proliferation rates. The de-differentiated SMCs 
also synthesize large amounts of extracellular matrix and form lesions which 
contribute to the restenosis and subsequent failure of the vascular intervention 
[52].  
 
1.3.3 Abdominal aortic aneurysm (AAA) 
Abdominal aortic aneurysm is a disease of the aorta demonstrated by 
arterial enlargement with predisposition to rupture which is associated with a high 
mortality rate [18, 24, 68]. Although AAA is an often asymptomatic progressive 
disease, the aorta may continue to enlarge progressively over months or years 
increasing the risk of rupture [18, 68]. Ruptured AAAs are the 13th leading cause 
of death in the United States and the 10th leading cause of death in Caucasian 
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men 65 – 74 years of age [18, 24, 69, 70]. The primary risk factors include male 
gender, advanced age and smoking [24]. In AAAs, the tissue lesion site is 
commonly characterized by elastin fragmentation, increased inflammation, and 
SMC depletion [24, 69, 71]. In addition, during the progression of AAAs, there is 
observable vascular SMC medial degeneration characterized by SMC apoptosis 
and reduction in medial SMC density compared with normal aortas [72]. Ailawadi 
et al (2009) reported reduced expression of the differentiation markers SM22α 
and SMα-actin in aneurysmal tissue obtained from animal and human studies, 
when compared with control aorta [53]. Furthermore, Jiao et al (2010) reported 
the decrease in the levels of SM22α, SM α-actin, and desmin in the vessel media 
during the development and progression of carotid artery aneurysms in rabbits 
when compared with those from control rabbits [73]. Current research in our lab 
using a mouse model of AAAs induced by chronic angiotensin II (AngII) infusion, 
demonstrated that progression of AAAs is also associated with reduced 
differentiation of SMCs in the abdominal aorta. However, the treatment of these 
mice with celecoxib, an inhibitor of the inducible cyclooxygenase-2 (COX-2) 
enzyme, was effective at attenuating AngII-induced AAA progression, and this 
was associated with maintenance of a differentiated SMC phenotype in the aorta 
[74, 75]. Even though the process of AAA formation and development involves 
complex pathological processes, a key factor in development of AAAs is the 
phenotypic modulation of vascular smooth muscle cells (VSMCs). 
Currently, there are no pharmacological agents for treating AAAs leaving 
surgery (open or endovascular repair) as the only option [70, 76]. Surgery to 
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repair AAA however, is not without its associated risks of morbidity and mortality, 
and thus, it is important to discover and develop effective non-surgical therapies 
for prevention and treatment of this disease. 
 
1.4 Prostanoids and cyclooxygenases 
Prostanoids are a family of cyclopentane derivatives of polyunsaturated 
fatty acids formed from arachidonic acid via the cyclooxygenase pathway and are 
important mediators of allergic reactions and inflammation [26, 77]. The 
cyclooxygenase (COX) enzymes catalyze the first step in the production of 
prostanoids. Two isoforms of the COX enzyme exist: COX-1, which is the 
constitutive enzyme, and COX-2, which is the inducible form. The amino acid 
sequences for both isoforms have about 75% homology, and the catalytic 
residues of these enzymes are highly conserved [78]. Both enzymes have 
different subcellular localizations as well as different tissue expression profiles 
with the COX-1 enzyme primarily associated with “housekeeping” functions in 
normal tissues such as hemostatic, gastric protection, and renal water balance 
[63, 79]. However, in response to stress, cytokines, growth factor stimulation, and 
inflammatory stimuli, COX-2 which is extremely low in most normal tissues 
(except in the kidney, testis, tracheal epithelium, and central nervous system) 
expression is increased. Also, macrophages are a major source of 
prostaglandins within the vessel wall. In addition, COX-2 expression is increased 
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in certain pathological conditions such as tissue injury, malignant transformation 
of gastrointestinal and mammary epithelium [79].  
The COX enzymes convert arachidonic acid into prostaglandin G2 (PGG2) 
via oxygenation, and then prostaglandin H2 (PGH2) which is synthesized from 
PGG2 via peroxidase activity is subsequently converted by tissue specific 
isomerases/synthases into different prostanoids including prostacyclin (PGI2), 
prostaglandin E2 (PGE2), prostaglandin D2 (PGD2), thromboxane (TXA2), and 
prostaglandin F2α (PGF2α) [80, 81]. Different cells exhibit differential expression of 
these synthases, thus determining the expression levels and production profiles 
of individual prostanoids under basal as well as inflammatory conditions. The 
cytoplasmic prostaglandin E2 synthase (cPGES), prostaglandin D2 synthase 
(PGDS), prostaglandin F reductase, and thromboxane A2 synthase (TXAS) are 
said to be preferentially coupled with COX-1, whereas the microsomal 
prostaglandin E2 synthase (mPGES-1), and prostacyclin synthase (PGIS) are 
often coupled and co-induced with COX-2 in response to acute and chronic 
inflammatory stimuli [82]. These prostaglandins exert their effects through their 
specific receptors, thus prostaglandin synthase inhibitors as well as receptor 
antagonists have been explored as potential therapeutic agents in the 
management of several diseases [26]. The role of various prostanoids in the 
pathogenesis of cardiovascular diseases has been extensively reviewed by 
Yuhki et al (2010) [83]. 
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1.4.1 Modulation of prostanoid activity 
The biological actions of these prostanoids may be modulated at the level 
of the cyclooxygenase enzymes, individual synthases or the prostanoid receptors 
[84]. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX-1 and/or COX-
2, thus limiting the production of prostanoids and the resulting inflammation 
produced by the action of these lipid mediators [82]. Deletion of COX-2 has been 
shown to result in re-diversion of arachidonic acid from the prostanoid synthesis 
pathway to increased synthesis of products of the 5-lipoxygenase pathway [67]. 
Furthermore, abnormal regulation of the COX-2 enzyme has been implicated in 
the pathology of numerous diseases including cancer, fever, Alzheimer’s 
disease, and cardiovascular diseases [85, 86]. 
 
1.4.2 Role of Prostanoids in vascular SMC phenotypic modulation 
1.4.2.1 Prostacyclin (PGI2)  
Prostacyclin (PGI2) was discovered in the 1970’s by John Vane and 
colleagues and observed to relax arteries and inhibit platelet aggregation [87]. 
Several studies have indicated that a balance between prostacyclin and 
thromboxane A2 (proaggregatory) contributes to maintaining the endothelial 
integrity and thrombus formation and overall vascular homeostasis [64, 88]. PGI2 
is a potent vasodilator, antithrombotic, and inhibitor of vascular SMC proliferation, 
leukocyte adhesion and platelet aggregation, and contributes to protection and 
maintenance of vascular homeostasis. PGI2 is the main prostaglandin product of 
arachidonic acid metabolism in the endothelial cells and is primarily synthesized 
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by the action of COX-2 [33, 63, 65, 89]. PGI2 is not stored, but exerts its effects 
locally and is converted rapidly non-enzymatically to its inactive metabolite, 6-
keto prostaglandin F1α (PG F1α) [89]. In certain cardiovascular disorders such 
as atherosclerosis, myocardial infarction, thrombosis, and pulmonary 
hypertension, reduced prostacyclin activity has been implicated [33]. 
PGI2 signaling 
Prostacyclin activity is mediated via its tissue-specific (predominantly 
platelets and vascular SMCs) G-protein coupled prostacyclin receptor (IP). 
Activation of the IP receptor results in Gs (G-protein) coupling resulting in 
activation of adenylate cyclase (AC), formation of cAMP, and subsequent 
activation of PKA [33] [64]. PGI2 activation of the IP receptor has also been 
reported to couple to Gq and mobilize Ca2+, whereas high concentrations of 
prostacyclin agonists have been reported to preferentially activate PPAR-α or 
PPAR-δ [64].    
It has been previously reported that prostacyclin and prostacyclin analogs 
induce differentiation in vascular SMC cultures [33, 52, 90]. Iloprost (prostacyclin 
analog) has been shown to induce SMC-specific differentiation markers and 
contractile morphology in cultured human vascular SMCs [33, 91, 92]. Recent 
studies by Tsai et al (2009) demonstrated that PGI2 induces SMC contractile 
phenotype, suggesting that a deficiency in PGI2 may result in SMC phenotypic 
alteration to the synthetic state [19]. Furthermore, treatment of vascular SMCs in 
the synthetic phenotype with varying concentrations of iloprost resulted in 
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induction of expression of SMC differentiation markers such as SMα- actin, SM2-
MHC, h-caldesmon and SM-MHC via activation of the downstream 
Gs/AC/cAMP/PKA pathway [33]. In addition, iloprost has been shown to induce 
expression of COX-2, upregulation of 6-keto PGF1α, in addition to inducing 
prostacyclin release in human vascular SMCs via independently-related 
prostacylin signaling pathways (cAMP/PKA and ERK1/2 activation), and the 
inhibition of Akt-1 signaling [92].   
Similarly, PGI2 has been implicated in reducing rates of proliferation and 
migration in VSMCs in vitro and in vivo [64]. Similar to COX-2 inhibition, defective 
PGI2 signaling via the IP receptor has been shown to be associated with increase 
adverse cardiovascular events [93]. Furthermore, Arehart et al (2008) 
demonstrated that defective human IP receptor increased the rate of 
atherothrombosis in patients attributable to decreased cAMP signaling in the 
platelets and VSMCs, which may contribute to reduced ability to inhibit 
thrombosis as well as VSMC proliferation and de-differentiation respectively [93]. 
 
1.4.2.2 Prostaglandin D2 (PGD2) 
PGD2 is a prostaglandin which has been shown to inhibit platelet 
aggregation and nitric oxide release, as well as act as an inductor of sleep and 
vasodilation [94]. Though there is paucity of information regarding the effect of 
PGD2 in modifying the phenotype of vSMCs, 15d-PGJ2 which is a stable naturally 
occurring metabolite of PGD2 has been demonstrated to increase mRNA 
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expression levels of differentiation markers, thus promoting smooth muscle cell 
differentiation [95-99]. This effect of 15d-PGJ2 may be mediated via activation of 
the peroxisome proliferator-activated receptor gamma (PPARγ) which is also 
expressed in VSMCs [100-102]. Furthermore, treatment of cultured human 
vascular SMCs with 15d-PGJ2 has been shown to promote differentiation [95-97]. 
PGD2 signaling 
There exist two forms of PGD2 synthase, lipocalin-type (L-PGDS) and 
hematopoietic-type (H-PGDS). L-PGDS is mainly responsible for PGD2 synthesis 
[94]. Also, two receptors, DP1 and DP2, are associated with PGD2 signaling. 
DP1 receptor activation due to ligand binding results in an increase in 
intracellular cAMP while DP2 receptor activation inhibits cAMP synthesis and 
increases intracellular calcium [82].  
 
1.4.2.3 Thromboxane A2 (TXA2) 
Thromboxane A2 (TXA2) is produced in platelets as well as in monocytes 
and VSMCs, and is involved in promotion of platelet aggregation and 
vasoconstriction [63, 77]. TXA2 has been shown to produce opposing actions to 
PGI2 in that TXA2 is a potent vasoconstrictor and platelet activator working in 
concert with PGI2 (vasodilator) to maintain vascular homeostasis [89]. An 
imbalance in the existence of both prostanoids may contribute to cardiovascular 
dysfunction observed in most vascular diseases [83].  
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TXA2 signaling  
TPα and TPβ are the two isoforms of the TP receptor, activation of which 
results in calcium ion mobilization [82] These TP isoforms may homodimerize 
(e.g TPβ/ TPβ) or heterodimerize with each other (TPα/TPβ), or with the IP 
receptor. The TP receptor may couple with Gq to activate PLC or with G13 to 
activate RhoGEF thus promoting platelet activation, aggregation and 
vasoconstriction [63]. 
 
1.4.2.4 Prostaglandin F2α (PGF2α) 
PGF2α is formed from the reduction of PGH2 due to the action of the PGF 
endoperoxide reductase/synthase (PGFS). However, this prostanoid may also be 
formed from PGE2 through 9-keto reductases or from PGD2 through 11-keto 
reductases [84]. Two forms of PGFS have been identified, PGFS-1 and PGFS-2, 
and two human splice variants of the FP (FPA, FPB) exist [82]. Activation of the 
FP receptor has been reported to trigger Gq protein signaling which may be 
linked to cellular proliferation or activation of Rho and may result in changes in 
cell cytoskeleton and morphology [84].  
 
1.4.2.5 Prostaglandin E1 (PGE1) 
PGE1 has been shown to induce and increase proliferation as well as the rate of 
phenotypic modulation of rat aortic SMCs from the contractile to the synthetic 
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state early in primary culture. However, later on in the culture, PGE1 inhibited 
DNA synthesis and cellular proliferation [77]. 
 
1.4.2.6 Prostaglandin E2 (PGE2) 
PGE2 is the principal prostanoid secreted during inflammation and is 
involved in production of proinflammatory cytokines resulting in alteration of 
vascular SMC contractile function, increased vascular permeability, dilation and 
pain [4, 52, 85, 103-105]. In addition, PGE2 has been reported to play a key role 
in epithelial physiology especially in gastrointestinal tissues [79]. PGE2 is 
synthesized by the action of the Prostaglandin E2 synthase (PGES) enzyme 
which exists in 3 isoforms: cytosolic (c-PGES), type 1 membrane-associated 
(mPGES-1) and type-2 membrane associated (mPGES-2) [106, 107]. cPGES 
and mPGES-2 are expressed constitutively, with cPGES coupling predominantly 
with the constitutive COX-1 enzyme while mPGES-2 couples with both COX-1 
and COX-2 [85, 105, 108, 109]. cPGES is a cytosolic protein constitutively 
expressed in a variety of tissues and is generally resistant to stimulation by 
proinflammatory stimuli [110, 111]. mPGES-2 is mainly expressed in the heart 
and brain, however, its biological function is not well described [111]. mPGES-1, 
(also known as microsomal prostaglandin E2 synthase) belongs to the MAPEG 
(membrane-associated proteins involved in eicosanoid and glutathione 
metabolism) superfamily [112]. This is the inducible isoform which is associated 
with the perinuclear membrane, and is generally found to be co-expressed and 
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functionally coupled with COX-2 in response to a range of extracellular and 
intracellular stimuli and downregulated by anti-inflammatory glucocorticoids [17, 
85, 106, 108, 111, 113-120]. In addition, in most cells, the most prominent PG 
produced during the delayed response is PGE2 associated with COX-2 
expression, and COX-2 inhibitors reduce PGE2 production more profoundly than 
the other prostanoids [85]. The majority of the PGE2 formed in response to COX-
2 induction is dependent on mPGES-1 [121-123]. Recent research has also 
demonstrated that PGE2 can also increase COX-2 expression. For example, 
PGE2 has been found to increase COX-2 and cPLA2 expression through 
activation of MAPK and NFκB pathways [124, 125]. In contrast however, 
Chandrasekharan et al (2005) reported that PGE2 production in the murine 
mammary gland depends on functional coupling of the COX-1 enzyme with 
mPGES-1[79].  
PGE2 signaling 
PGE2 activity is modulated via activation of its G-protein-coupled 
receptors: EP1, EP2, EP3 and EP4 which are structurally and functionally distinct 
[105, 126]. These receptors have unique tissue expression profiles and their 
effects are mediated through different downstream signaling pathways [79, 127-
129]. EP2 and EP4 are coupled to Gs and activation of these receptors cause 
increases in intracellular cAMP levels. Furthermore, EP4 signaling pathway may 
involve phosphatidyl inositol 3-kinase (PI3K), resulting in protein kinase B (Akt) 
and extracellular signal-related kinases (ERK) activation [83]. The EP3 receptor 
which has 8 different splice variants is coupled to both G1 and Gq; and activation 
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may result in increased intracellular Ca2+ levels, reduce, or increase cAMP 
production depending on the expression of the EP3 splice variant(s) in the cell 
[79, 82].  
In vascular SMCs, the effects of PGE2 in regulating differentiation will 
depend on the EP receptor(s) expressed in the cell type. Studies have shown 
differential expression of the different EP receptors in various disease states and 
cell culture models [5, 104, 130, 131]. For example, a variety of the EP receptors 
including EP2, EP3, and EP4 have been shown to be expressed in cultured 
SMCs obtained from AAA tissues, however only EP2 and EP3 receptors were 
found in cultured human aortic smooth muscle cells [126]. Expression of these 
receptors has also been shown to be dependent on vascular SMC culture 
conditions, with EP4 showing greatest expression and EP1 and EP2 being 
undetectable under growth-promoting conditions [132]. EP4 receptor protein has 
been shown to be present in AAA lesions of both mice and human samples and 
inhibition of this receptor in mice results in reduction of the incidence and severity 
of AAAs [133, 134].  
  PGE2 has been demonstrated to alter actin organization in cultured rat 
vascular SMCs, which may indicate an effect on de-differentiation [104]. In 
addition, hyaluronan synthase and MMP activity, which are characteristics of the 
de-differentiated phenotype, have been shown to be stimulated by PGE2 in 
several cell culture and vascular disease models [34, 135-141]. In other cell 
types, EP receptor expression has been shown to change under different states 
of differentiation. In chondrocytic cells for example, increased COX-2 expression 
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was shown to correlate with increased expression of EP2 and EP3a1 mRNA, 
whereas no change was observed with the EP1 and EP4 receptors [142]. In 
addition, reduced differentiation of renal glomerular cells induced by PGE2 was 
suggested to occur via EP4 upregulation and activation [143]. Furthermore, 
expression of EP4 in the ductus arteriosus, has been shown to increase with 
advancing gestational age [144, 145]. Thus, these reports suggest that there are 
changes in EP receptor expression under different states of cell differentiation.  
Even though individual prostanoids and their analogs demonstrate a high 
degree of cognate receptor selectivity, the level of specificity depends on the 
ligand concentration, as prostaglandin analogues selective for one receptor at a 
given concentration may lose selectivity at higher concentrations and exhibit 
cross-reactivity with multiple prostanoid receptors [146]. The potential for 
nonselective effects of prostanoids or analogues increases the complexity of 
identifying novel functions of these mediators. The complexity of analysis is 
further enhanced given that prostanoid action involves the enzymatic activity of 
phospholipases, cyclooxygenases, and prostanoid synthases, together with 
specific receptors activating unique intracellular events. Therefore, the complete 
characterization of a prostanoid-dependent biological response may require the 
understanding of coordinated processes involving numerous enzymatic and 
signaling pathways.  
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CHAPTER 2: HYPOTHESIS AND SPECIFIC AIMS 
Abdominal aortic aneurysm (AAA) is a cardiovascular disease affecting 1 in 
every 10 adults over 55 years of age. Ruptured AAAs are the 13th leading cause 
of death in the United States and the 10th leading cause of death in Caucasian 
men 65 – 74 years of age in the United States. It is characterized by progressive 
dilation of the aorta within the abdominal region which may result in rupture and 
sudden death if left. Unfortunately, there are no medications approved for the 
prevention or treatment of this disease leaving surgery is the only option. Surgery 
to repair AAA however, is associated with significant risk of morbidity and 
mortality, and is therefore reserved for the most severe cases of the disease. For 
patients with smaller aneurysms who do not qualify for surgical repair however, 
the medical approach recommended is “watchful waiting” [18, 24, 69, 70, 76]. 
Recent findings have demonstrated that during the development of this 
disease, one of the characteristics observed during the pathological remodeling 
observed within the aorta is the alteration of the differentiation state of the 
vascular smooth muscle cells (SMCs) within the aneurysmal lesion. The cells in 
the contractile differentiated state undergo a process of de-differentiation into the 
synthetic de-differentiated state which is characterized by a loss in the 
expression of differentiation markers and increase expression of markers of the 
synthetic phenotype. In human biopsies obtained from patients undergoing 
aneurysmal repair, Ailawadi et al observed increased expression of markers of 
the de-differentiated phenotype and decreased expression of markers of the 
differentiated phenotype compared with normal aorta [53]. Furthermore, using a 
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mouse model of AAAs induced by chronic angiotensin II (AngII), the progression 
of AAAs has been shown to be associated with reduced differentiation of SMCs 
in the abdominal aorta. The treatment of these mice with celecoxib, an inhibitor of 
the inducible cyclooxygenase-2 (COX-2) enzyme, was effective at attenuating 
AngII-induced AAA progression, and this was associated with maintenance of a 
differentiated SMC phenotype in the aorta [74]. These findings suggest that 
COX-2 may play a role in altering the differentiation state of SMCs within the 
aorta during development of this disease. 
Together with COX-2, other components of the prostanoid synthesis pathway 
have been implicated in the pathogenesis of AAA. In aneurysmal tissue, the 
increased expression of COX-2 and microsomal prostaglandin E synthase-1 
(mPGES-1), and the increased synthesis of prostaglandin E2 (PGE2) have been 
observed, as compared to uninvolved aorta [71, 126, 147-151]. Genetic 
inactivation or pharmacological inhibition of COX-2 in mouse AAA models 
significantly reduces AAA incidence and severity compared with wild-type mice 
[71, 148]. Even at the site of ruptured AAAs in humans, the COX-2 gene was 
found to be overexpressed in aneurysmal lesions compared to normal aortic 
tissues [151]. Wang et al (2008) demonstrated that deletion of mPGES-1 (an 
enzyme that acts downstream of COX-2) in AngII-induced AAA mouse models 
significantly attenuated the incidence and severity of AAAs [128]. Similarly, 
pharmacological or genetic inhibition of the prostaglandin E subtype 4 receptor 
(EP4) also attenuates the incidence and severity of AAAs in both human and 
mouse models of this disease [133, 134]. Despite these promising findings 
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however, because certain COX-2 inhibitors have been associated with increased 
risk of adverse side effects in humans, COX-2 inhibitors have not been approved 
for treatment of this disease in patients. It is therefore important to identify 
mediators downstream of this enzyme which will provide new targets for the 
treatment of this disease.  
With previous findings of the effectiveness of COX-2 inhibition in attenuating 
the development and progression of AAAs in a mouse model being associated 
with maintenance of a differentiated SMC phenotype, the primary objective of the 
current research is to identify mechanisms by which COX-2 affects SMC 
differentiation using an in vitro cell culture model of human aortic smooth muscle 
cells (hASMCs). In order to examine this, the following hypothesis was proposed 
: Increased prostaglandin E2 (PGE2) synthesis in the hASMCs due to the 
induction of COX-2 and mPGES-1 may result in reduced differentiation of SMCs, 
and that disruption of this pathway would preserve the differentiated phenotype. 
hASMCs were utilized to assess the role of COX-2 and mPGES-1-dependent 
production of prostaglandin E2 (PGE2) in contributing to reduced SMC 
differentiation. This project has 3 specific aims:   
 
(1) Examine the role of COX-2 in hASMC phenotypic modulation  
a. Correlate COX-2 levels with changes in the hASMC phenotype in vitro 
b. Investigate the effect of pharmacological inhibition of COX-2 on the hASMC 
phenotype 
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(2) Investigate the importance of AngII in hASMC phenotypic modulation 
a. Examine the effect of AngII treatment on the hASMC differentiation state 
b. Correlate AngII-induced phenotypic changes with the expression of COX-2 
and mPGES-1  
 
(3) Determine the role of PGE2 synthesis by COX-2 and mPGES-1  in the 
induction of hASMC de-differentiation  
a.  Examine the effect of exogenous PGE2 treatment on hASMC phenotypic 
modulation. 
b. Determine the effect of pharmacological inhibition of mPGES-1 on preventing 
hASMC de-differentiation 
c. Using siRNA mediated knock-down of mPGES-1, determine the effect of 
reduced mPGES-1 expression and PGE2 synthesis on preventing de-
differentiation 
 
A better understanding of the role of the COX-2/mPGES-1/PGE2 pathway in 
hASMC de-differentiation will be an important step forward in the discovery and 
development of therapeutics for manipulation of the SMC phenotype, where 
altered SMC differentiation may be a significant contributor to disease 
progression. 
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Cell culture 
Human aortic smooth muscle cells (hASMCs) were purchased from 
Cascade Biologics (Invitrogen) and cultured according to manufacturer 
instructions using recommended media (Medium 231) with supplements to 
induce either growth or differentiation. The basal culture medium used (Medium 
231) was made up of essential and non-essential amino acids, vitamins, other 
organic compounds, trace minerals, and inorganic salts [152]. Growth promoting 
media was supplemented with 4.9% fetal bovine serum (FBS), heparin (5 ng/ml), 
human basic fibroblast and epidermal growth factors (2 ng/ml and 0.5 ng/ml 
respectively), and recombinant human insulin-like growth factor (2 µg/ml). 
Differentiation-promoting media was made up of Medium 231 supplemented with 
1% FBS, and heparin (30 µg/ml). Both growth-promoting and differentiation-
promoting media also contained 1% penicillin and streptomycin. Cells used in all 
experiments were from passages 2 – 8 and were cultured in a humidified 5% 
CO2 atmosphere at 37oC. Cells were cultured under either growth-promoting 
conditions with growth-promoting media, or under differentiation-promoting 
conditions with differentiation-promoting media. Varying concentrations of drugs 
or prostanoid receptor agonists/antagonists were used to treat cells prior to lysis 
and harvest after specific time periods.  
In order to induce differentiation in cells cultured under growth-promoting 
conditions, the cell media was replaced with serum-deprived media and 
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maintained under these conditions over time. In order to induce expression of 
COX-2, or mPGES-1, growing cells were serum-starved overnight and then re-
stimulated with serum-containing growth-promoting media.  
 
3.1 Cell lysis and protein collection 
After cell culture and treatment, cell culture media were either collected for 
further analyses or discarded at pre-determined time points and adherent cells 
were rinsed briefly two times with 1XPBS. Cells were lysed with equal volumes of 
RIPA lysis buffer made up of 200 mM Tris with pH 7.6, glycerol, 10% SDS, 10% 
deoxycholate, Triton X-100, 200 mM EDTA containing protease and 
phosphatase inhibitors (PMSF and leupeptin). Cells lysates were subsequently 
scraped and pipetted into 1.5 ml Eppendorf tubes for storage at -20oC until 
further use.  
Prior to protein separation via SDS PAGE, protein content in each sample 
was analyzed using the Bicinchoninic Acid (BCA) method and specific volumes 
corresponding to equal amounts of protein was added to fixed volumes of loading 
buffer and heated at 100oC for 10 minutes. The loading buffer was made up of 
0.5 M Tris (pH 6.8), glycerol, 10% SDS, 0.5% bromophenol and 5% β-
mercaptoethanol. After heating, the tubes were vortexed briefly, spun-down using 
a microcentrifuge and then loaded unto polyacrylamide gels for protein 
separation via western blotting. 
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3.3 Western Blot Analysis 
Equal amounts of cell lysates were loaded unto 12% polyacrylamide gels, 
separated via SDS-PAGE and transferred unto nitrocellulose membranes (GE 
Healthcare). Membranes were blocked for 1 hour with 5% bovine serum albumin 
in Tris-buffered saline containing 1% Tween 20. Blots were then incubated 
overnight at 4oC with specific primary antibodies. Antibodies against SMα-actin 
(Sigma Aldrich), and SM22α (Abcam Inc.), were used as markers of 
differentiation while de-differentiation was measured by a corresponding 
decrease in these protein markers. Either α-tubulin (Cell signaling) or calnexin 
(Cell signaling) were used as loading controls. Monoclonal α-actin primary 
antibody was fluorophore conjugated with Cy3, while biotinylated anti-rabbit 
secondary antibodies together with fluorophore-conjugated streptavidin 
complexes were used for detection of SM22α, α-tubulin and calnexin. For COX-2 
(Vector laboratories) and mPGES-1 (Oxford biomedical research) detection, 
horse-radish peroxidase (HRP)-conjugated anti-rabbit IgG were used as 
secondary antibodies. Protein detection of fluorophore-conjugated antibodies 
was done via fluorescence imaging using the Typhoon laser scanner (GE 
Healthcare), while HRP-conjugated antibodies were detected by enhanced 
chemiluminescence. Images were analyzed and quantified via densitometry 
using the Imagequant analysis software (GE Healthcare). 
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3.4 mRNA isolation  
mRNA was isolated from the hASMCs using the RNeasy kit (Qiagen Inc., 
CA, USA) according to manufacturer’s instructions. The procedure combines 
selective binding properties of a silica-based membrane with the speed of 
microspin technology [153]. Briefly, cultured cells were lysed and homogenized 
with QIAshredder spin columns in the presence of a highly denaturing guanidine-
thiocyanate-containing buffer which inactivates RNases, thus ensuring 
purification of intact RNA. Next, one volume of 70% ethanol was added to the 
homogenized lysate, thus providing appropriate binding conditions and then 
transferred to an RNeasy spin columns thus ensuring that total RNA binds to the 
membrane and contaminants are washed away. Subsequent washes of the spin 
columns with RNase-free water yielded high quality RNA elutes for further 
analysis.  
 
3.5 cDNA preparation via reverse transcription 
Total RNA was reverse transcribed in a two-step process adapted from an 
InvitrogenTM protocol [154]. The first step consisted of adding mRNA to a mix 
containing random hexamers (1: 60 dilution), deoxynucleotide triphosphate mix 
(dNTPs), and DEPC water in Eppendorf tubes. This mixture was heated for 5 
minutes at 65oC on a thermal cycler (Eppendorf). To this was added a second 
mix consisting of 5X reverse transcription buffer, 0.1 M DTT (dithiothreitol), 
RNAse inhibitor, and Superscript II reverse transcriptase. Eppendorf tubes 
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containing the final mixture were placed back on the thermal cycler and then 
heated at 25°C for 10 minutes and then increased to 42°C for 50 minutes. After 
these heating cycles, the reaction was terminated by heating at 70°C for 15 
minutes and the tubes were stored at -20°C prior to being used for gene 
expression analysis. 
 
3.6 Quantitation of gene expression via RT-PCR 
mRNA expression and quantitation of gene expression was performed via 
the two-step Real-Time Polymerase Chain Reaction (RT-PCR) procedure. Here, 
the PCR step using Superscript II (Invitrogen) was coupled with fluorogenic 5’ 
nuclease chemistry (Taqman) using primer/probe assays for smooth muscle α-
actin, SM22α, COX-2, microsomal PGE2 synthase (mPGES-1), matrix 
metalloproteinase -2 (MMP-2), smoothelin, myosin heavy chain 2 (MyhII), and 
hyaluronan synthase 2 (Has2) (Applied Biosystems (Foster City, CA). mRNA 
expression of the constitutively expressed housekeeping gene hypoxanthine 
phospho-ribosyl transferase (HPRT) was quantitated as an internal normalizing 
control gene. Relative gene expression levels were calculated by comparing 
cycle times for each target PCR using the the ∆∆ct method. To do this, the target 
PCR Ct values were normalized by subtracting the HPRT Ct value, to give the 
∆Ct value. The relative expression levels between treatments were then 
calculated using the equation: relative gene expression = 2−(∆Ctsample-∆Ctcontrol) 
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3.7 PGE2 Enzyme Immunoassay 
PGE2 concentrations in cell culture media were determined using a PGE2 
enzyme immunoassay (EIA) monoclonal kit according to the manufacturer’s 
protocol (Cayman chemical company). This is a competitive assay between the 
PGE2 present in the cell culture media and a PGE2-acetylcholinesterase 
conjugate (PGE2 tracer) for a limited amount of PGE2 monoclonal antibody [155]. 
The wells in the plate are pre-coated with goat polyclonal anti-mouse IgG and 
blocked with a proprietary formulation of proteins. Each well is incubated with a 
fixed amount of the PGE2 tracer, cell culture media containing free PGE2 and 
specific PGE2 monocolonal antibody for approximately 18 hours and stored at 
4oC. Since the amount of PGE2 in the media varies, the amount of PGE2 tracer 
that is able to bind to the PGE2 monoclonal antibody will be inversely proportional 
to the concentration of PGE2 in the well. The antibody-tracer complex binds to 
the goat polyclonal anti-mouse IgG used to pre-coat the wells. After incubation, 
the mixture is discarded from the wells and after a series of wash steps, Ellman’s 
reagent which contains a substrate to the acetycholinesterase is added to the 
wells and the plate is placed on an orbital shaker and kept in the dark for 75 
minutes to develop. An enzymatic reaction occurs between the 
acetylcholinesterase and the substrate producing a yellow color which absorbs 
strongly at 412 nm. The absorbance of the solution based on the intensity of this 
color is determined spectrophotometrically using a plate reader set to 405 nm. 
The amount of free PGE2 present in the well is inversely proportional to the 
amount of PGE2 tracer bound to the well during the incubation. 
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3.8 Immunocytochemistry 
hASMCs were plated onto 12 or 24 well plates, fixed with 4% 
paraformaldehyde and permeablized with 0.5% Triton X-100. After blocking with 
1% bovine serum albumin (BSA) for 1 hour, cells were incubated overnight in 
either Cy3-conjgated primary antibody for SMα-actin-Cy3 antibody (in 1%BSA) at 
4oC. Alternatively other primary antibodies were detected with Cy3-conjugated 
secondary antibodies. Cell nuclei were visualized with SYBR green (AB systems) 
after incubation for 45 minutes at room temperature. Cells were washed with 
1XPBS and plates were scanned and images were captured by the GE 
Healthcare Typhoon fluorescence imager after each incubation. Using the 
ImageJ analytical software, quantitation of fluorescent intensity/densitometry was 
obtained and the ratio of α-actin to SYBR green was expressed as the extent of 
differentiation observed in these cells. 
 
3.9 mPGES-1 RNA interference via siRNA transfection 
hASMCs were transfected with mPGES-1 siRNA using the 
Lipofectamine® RNAiMAX transfection reagent (Invitrogen, NY USA), and 
following the reverse transfection protocol as outlined by the company. 82.5 nM 
of predesigned annealed siRNA targeted to mPGES-1 (siRNA ID 15540, Life 
Technologies) and 3 uL of transfection agent were pre-plated onto empty 12 well 
plates and then cell suspension in growth media was added to the wells. After 
two days, the growth media was replaced with serum-free media for either 1 or 2 
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days, and cell media was collected for PGE2 EIA analysis. Both protein and 
mRNA samples were isolated from replicate treatments of these cells and 
analyzed for phenotypic changes via western blotting or real time PCR 
respectively.  
 
3.10 Statistical analyses 
Each experiment was repeated at least three times and statistical 
analyses were carried out using the GraphPad Prism software version 5.04 
(GraphPad Software Inc., San Diego, CA Prism 5.04). The mean and SEM were 
calculated for each parameter with a single treatment considered as n of 1. 
hASMC phenotype comparisons between differentiated and de-differentiated 
cells were analyzed by two-way repeated measures ANOVA. Bonferroni post 
tests were used where indicated. To compare the significance of the difference 
between 3 or more treatment groups, one-way ANOVA test, followed by the 
Dunnett’s multiple comparison post-hoc tests was utilized. Unpaired Student’s t 
test was used to compare the effects observed between two groups. Statistical 
significance was defined as P < 0.05. 
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CHAPTER 4: CHARACTERIZATION OF THE HUMAN AORTIC SMOOTH 
MUSCLE CELL PHENOTYPE 
Introduction 
Phenotypic modulation is a unique characteristic of vascular SMCs 
demonstrated by their ability to switch their phenotype between the contractile or 
differentiated phenotype to the synthetic or de-differentiated phenotype in 
response to various external cues such as growth factors, inflammatory 
mediators, and cytokines [8-18]. These cells do not differentiate terminally but 
retain sufficient plasticity to switch back and forth along a continuum between the 
differentiated and de-differentiated phenotypes. This unique characteristic of 
vascular SMCs in phenotypic modulation is important in the regulation of 
vascular function in health and disease. Both phenotypic states are simply two 
extremes of the spectrum of vascular SMC phenotypic expression since cells 
expressing features of both phenotypes do exist [19-21].  
The principal function of vascular SMCs within the vasculature is 
contraction, and this is mediated by the action of contractile proteins which are 
expressed at increased levels in mature differentiated SMCs. The action of SMC 
contraction and relaxation results in the alteration of the luminal diameter of the 
blood vessels and contributes to the regulation of blood pressure and blood flow 
[12, 46, 52]. Normal mature vascular SMCs exist in a quiescent non-proliferative 
state and demonstrate a well-differentiated contractile phenotype. Cells in this 
differentiated phenotype express greater levels of SMC contractile proteins such 
as smooth muscle α-actin, SM22α, SM myosin heavy chain, and smoothelin 
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compared with cells in the synthetic phenotype [7, 12, 24-29]. Furthermore, cells 
in the contractile phenotype proliferate slowly while expressing low levels of 
extracellular matrix proteins. On the contrary, cells in the de-differentiated 
phenotype express increased levels of synthetic markers such as hyaluronan 
synthase, collagens, and matrix-metalloproteinases, and have increased 
proliferation and migration rates [12, 16, 26, 28, 30-34].  
Alteration of the differentiated vascular SMC phenotype plays a key role in 
contributing to vascular pathology. In certain vascular disorders such as 
atherosclerosis, restenosis following vascular injury, hypertension, and 
abdominal aortic aneurysms, a decrease in protein and mRNA expression of 
SMC differentiation markers has been observed. This results in a change from 
the differentiated to the de-differentiated phenotype within the SMCs of the 
affected regions within the vascular wall. An important characteristic of this 
change from the differentiated to the de-differentiated phenotype involves the 
increased synthesis of extracellular matrix components, such as collagen, 
hyaluronic acid and elastin [9, 30, 46-53]. The de-differentiation process, is also 
associated with the re-entry of the SMCs into the cell cycle which is accompanied 
by increased proliferation and migration rates [52]. This phenotypic shift to a less-
differentiated phenotype, characterized by the reduction in differentiation markers 
and increase in markers of the synthetic phenotype may be a crucial component 
of the repair process [46]. When the vascular injury is resolved, the 
environmental cues within the vessel change, causing the SMCs to reacquire 
their normal contractile phenotype [9].  
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The addition of heparin to cell culture media and/or reduction of serum 
concentration are methods that have been shown to induce and maintain 
differentiation in smooth muscle cells. Heparin is a natural glycosaminoglycan 
demonstrated to possess potent anti-proliferative and anti-migratory activity in 
vascular smooth muscle cell in vitro and in vivo [156, 157]. Various molecular 
mechanisms have been proposed for these actions in vascular SMCs. Heparin 
has been shown to induce cell cycle arrest [158, 159], inhibit production of matrix 
degrading enzymes [156, 160], regulate expression of extracellular matrix 
proteins [161] induce growth-arrest specific genes [162, 163] and to inhibit the 
activation of mitogen-activated genes [164]. In addition, heparin has been shown 
to also promote the contractile phenotype in vascular SMCs by increasing 
differentiation marker expression [165-168]. This characteristic of heparin has 
been demonstrated to be mediated in part by the increase in TGFβ secretion, a 
factor known to enhance the differentiation of SMCs [9, 169-171].  
In addition to induction of vascular SMC differentiation by heparin, the 
complete removal of serum albumin (serum deprivation) from cell culture media 
has been demonstrated to promote the differentiated phenotype in vascular 
SMCs [23, 44, 172, 173]. When SMCs are cultured under serum-free conditions 
over time, these cells are induced to differentiate with acquisition of the requisite 
morphology, contractile ability and increased expression of SMC differentiation 
markers at comparable levels to that of differentiated cells [23]. However, this 
induction of differentiation has been shown to be reversed upon administration of 
growth factors, or serum-containing media [172, 174].  
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Although a variety of different growth factors have been shown to induce 
the synthetic phenotype, the identification of factors responsible for inducing the 
contractile phenotype has been limited. One such endogenous factor that has 
been proposed to maintain a differentiated phenotype under conditions of serum-
deprivation is the cellular repressor of E1A-stimulated genes (CREG). CREG is 
upregulated under conditions of serum-deprivation and has been shown to 
promote differentiation by increasing expression of contractile markers, inhibiting 
cell proliferation, and inhibiting the synthetic phenotype of vascular SMCs under 
these conditions [175].  
In contrast to agents that promote differentiation, the presence of a variety 
of growth factors, and/or increased serum concentrations in the cell culture 
medium have been demonstrated to promote cell proliferation, migration, and 
phenotypic modulation from the contractile to the synthetic state in vascular 
SMCs [6, 166, 167, 174, 176, 177]. Peyton et al (2002) demonstrated that 
increased serum (10%) promotes vascular SMC proliferation by the induction of 
heme oxygenase (HO-1) mRNA and protein expression. This serum-induced 
increase in DNA synthesis was observed both in the presence and absence of 
growth factors [178]. Similarly, increased serum and/or growth factor stimulation 
in vascular SMCs have been observed to promote synthesis of proteoglycans 
thereby promoting the synthetic SMC phenotype [179]. Furthermore, platelet-
derived growth factor (PDGF) has been shown to destabilize the cytosolic α-actin 
mRNA pool at the transcriptional level resulting in significant reduction in actin 
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mRNA and protein, thus promoting the de-differentiated SMC phenotype [180, 
181].  
To characterize the phenotype of our in vitro cell culture model, human 
aortic smooth muscle cells (hASMCs) were cultured under different media 
conditions and the effect of culture media on the SMC phenotype was examined 
by measuring mRNA expression and protein levels of different markers of both 
the contractile and synthetic phenotypes.  
 
Results 
4.1 Induction of phenotypic modulation by cell culture media 
4.1.1 α-actin and SM22α are expressed at greater levels in the differentiated 
phenotype compared with the de-differentiated phenotype 
To induce differentiation in hASMCs, cells were cultured in differentiation-
promoting media while de-differentiation-promoting media was used to promote 
the synthetic phenotype. Compared to media promoting the de-differentiated 
phenotype, differentiation-promoting media was made up of increased amounts 
of heparin (6000-fold) and reduced amounts of fetal bovine serum (1%). On the 
other hand, de-differentiation-promoting media contained increased serum (5-
fold), reduced heparin, and a variety of growth factors.  
Cells were cultured under both conditions over time and after each time 
point, cells were lysed and then either harvested for analysis via western blotting 
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or alternatively, mRNA was collected for real-time PCR analysis. Significant 
increase in α-actin and SM22α were used as the major markers of differentiation.  
The level of α-actin expression was compared between differentiated (DC) 
and de-differentiated conditions (d-DC) at each individual time-point. Significantly 
increased α-actin mRNA expression was observed in cells cultured under 
differentiation-promoting conditions compared with cells cultured under de-
differentiation-promoting conditions at each time point (Figure 4.1A). This finding 
was also observed in the protein levels of α-actin with significantly greater levels 
observed in cells cultured under differentiation-promoting conditions compared 
with cells cultured under conditions promoting de-differentiation. In addition, over 
the 5-day time period there was a significant increase in α-actin protein levels in 
cells cultured under conditions promoting differentiation but this was not 
observed under de-differentiation promoting conditions (Figure 4.1B). With 
SM22α, significantly increased protein levels was observed in cells cultured 
under differentiation promoting conditions but this increase ceased to be 
significant beyond the 3rd day (Figure 4.1C).  
In addition, even though protein levels of both α-actin and SM22α were 
significantly increased under conditions promoting differentiation compared with 
growth, there was greater increase in the expression levels of α-actin compared 
with SM22α. There was a 12-fold increase in α-actin levels at the 5 day time-
point when compared with 1 day in cells cultured under differentiation-promoting 
conditions. For SM22α however, the increase observed was only 5-fold. 
Furthermore, the fold increase in protein levels when comparing cells in 
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differentiation media to growth at every time point was greater with α-actin than 
SM22α (Figure 4.1.1B & C). 
Figure 4.1.1 α-actin and SM22α are expressed at greater levels in the 
differentiated phenotype compared with the de-differentiated phenotype 
(A) mRNA expression of α-actin in hASMCs cultured for 1 to 4 days under 
conditions promoting differentiation or growth. Densitometry and representative 
western blot showing protein levels of (B) α-actin and (C) SM22α, in hASMCs 
cultured for 1 to 5 days under conditions promoting differentiation (DC) or de-
differentiation (d-DC). Data represents mean + SEM (n≥3), * = p < 0.05, ** = p < 
0.01, *** = p < 0.001, and **** = p < 0.0001; two-way ANOVA used to determine 
differences due to culture media and time. Bonferroni multiple comparisons 
examining α-actin expression due to culture media were conducted within each 
time point. α- actin expression after 1 day in differentiation-promoting media was 
used as control. 
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was isolated and analyzed for HAS2 expression via real time PCR. An increase 
in HAS2 was used to indicate de-differentiation in these cells. 
In contrast to α-actin and SM22α expression patterns, cells cultured under 
differentiation-promoting conditions expressed significantly lower levels of HAS2 
at each time point compared with cell cultured under conditions promoting de-
differentiation. Furthermore, under both conditions over time, HAS2 expression 
was significantly reduced evidenced by greater expression of HAS2 after 1 day 
compared with 2 days. 
Figure 4.1.2 HAS2 expression is increased in the synthetic phenotype  
mRNA expression of HAS2 in hASMCs cultured for 1 or 2 days under conditions 
promoting either differentiation or de-differentiation. Data represents mean + 
SEM (n≥3), **** = p<0.0001; two-way ANOVA to determine differences in HAS2 
expression due to culture media and time. Bonferroni multiple comparisons 
examining HAS2 mRNA expression due to culture media at each time point.  
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4.2 Induction of differentiation by serum-deprivation 
As seen in Figure 4.1, cells cultured over time in differentiation-promoting 
media are induced to express increased levels of differentiation markers with a 
significant increase in levels of α-actin and SM22α right from the first day of 
culture. As an alternative method of inducing differentiation and examining the 
effects of various treatments under conditions without the potential for interaction 
with serum-containing components, cells were cultured in de-differentiation-
promoting media for 2 days and then deprived of serum over time. Cells were 
lysed and harvested daily over a 5-day time period and subsequently analyzed 
for protein levels of differentiation markers (α-actin and SM22α) via western 
blotting. Cells cultured for 2 days under conditions promoting de-differentiation 
which were not exposed to the serum-deprived medium were utilized as controls.  
Control cells expressed nearly undetectable levels of α-actin and SM22α 
and these levels remain reduced even after introducing serum-free medium to 
these cells for 1 day. However, after 2 days in serum-deprived media, the cells 
began to express increased levels of α-actin, and this trend was significant after 
3 to 5 days of serum-deprivation compared to controls. With SM22α protein 
levels, significant increase was observed from the 3rd day in serum deprivation 
media up to the 5-day time point. Compared to controls, the increase observed in 
α-actin protein levels over time was much greater than with SM22α protein 
levels. At the 3 day time point, α-actin levels were about 20-fold greater while 
about a 1.5-fold increase was observed with SM22α. By the 5th day in serum-
deprivation media, over a 50-fold increase was observed with α-actin, whereas 
 o
 
F
D
a
fo
m
A
 
 
 
 
 
nly about a
igure 4.2 S
ensitometr
ctin and (B
r 5 days. C
ean + SEM
NOVA and
α-actin 
α-tubulin 
 3-fold incr
erum dep
y and repre
) SM22α, in
ontrol cells
 (n≥3), * =
 post hoc a
ease was o
rivation ov
sentative w
 hASMCs 
 were not 
 p < 0.05, *
nalysis wit
44 
bserved w
er time in
estern blo
cultured un
exposed to
** = p<0.00
h Dunnett’s
ith SM22α
duces diff
t showing 
der condit
 serum-free
1, **** = p
 Multiple C
. 
erentiation
protein leve
ions of seru
 media. D
 < 0.0001; 
omparison
 
 in hASMC
ls of (A) α-
m-depriva
ata represe
one-way 
 test. 
s 
tion 
nts 
 F
 
 
D
v
q
s
p
p
w
h
igure 4.2 (
 
iscussion
Norm
ascular sm
uiescent st
uch as athe
athological
rocesses, a
ith decreas
as been re
SM22α 
α-tubulin 
continued
 
al mature b
ooth muscl
ate. Howev
rosclerosis
 remodeling
 phenotyp
ed mRNA 
ported [9, 4
). 
lood vesse
e cells that
er, during 
, restenos
 of the ves
ic switch fro
and protein
6-53, 175]
45 
ls under p
 exist in the
the progres
is due to va
sel wall is 
m the con
 expressio
.  
hysiologica
 contractile
sion of car
scular inju
observed. 
tractile to t
n of SMC m
 
l condition
, differenti
diovascula
ry, and aor
During thes
he syntheti
arkers of 
s possess 
ated, and 
r diseases 
tic aneurys
e disease 
c phenotyp
differentiat
ms, 
e 
ion 
46 
 
Both α-actin and SM22α are proteins which have been shown in the 
literature to be markers of the differentiated state [184-186]. Greater levels of α-
actin are expressed in mature, differentiated vascular SMCs and this actin 
isoform is the predominant marker of differentiation in these cells. Furthermore, 
α-actin is the single most abundant protein in the cells, accounting for 
approximately 40% of the cell protein population [46]. As shown in Figure 4.1.1A 
& B, α-actin mRNA and protein levels were significantly increased at each time 
point in hASMCs cultured under conditions promoting differentiation, as 
compared to cells under de-differentiation-promoting conditions. This significant 
increase was consistent over multiple days of culture, thus suggesting that the 
quantitation of α-actin protein expression is an effective method of identifying the 
differentiated state in these hASMCs. In addition, the interaction between both 
the cell culture media as well as the duration of cell culture both have a 
significant effect on the increased expression of α-actin in hASMCs cultured 
under conditions promoting differentiation. 
SM22α is a 22 kDa protein which serves as an actin-association protein 
involved in organization of the vascular SMC cytoskeleton and the regulation of 
vascular function [187]. This protein is also a well-established marker of the 
differentiated smooth muscle phenotype, as increased levels have been 
observed with vascular SMC differentiation [184-186, 188]. In these hASMCs, a 
significant increase in SM22α protein levels with differentiation-promoting 
conditions was observed, as compared to cells cultured under conditions 
promoting de-differentiation. However, this effect was seen only during the first 3 
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days of culture (Figure 4.1.1C). Compared with the differentiation-promoting 
media, the de-differentiation promoting media, which contained an increased 
concentration of serum together with the presence of additional growth factors, 
effectively induced de-differentiation of these hASMCs. In contrast, the 
contractile phenotype produced by the differentiation media resulted from the 
absence of high serum and additional growth factors, together with the presence 
of increased levels of heparin [6, 165-168, 174, 176, 177]. 
Increased confluence of vascular smooth muscle cells in-vitro has been 
demonstrated to increase expression of markers of differentiation. There was no 
significant difference in SM22α levels between cells cultured under 
differentiation- or growth-promoting conditions at the 4 or 5 day time-points. 
Furthermore, in cells cultured under conditions promoting de-differentiation 
significant increase in the levels of α-actin and SM22α at the 5-day time point , 
was observed compared to 1 day. The tendency of differentiation marker 
expression to increase in cells cultured under de-differentiation-promoting 
conditions for prolonged time may be as a result of increased cell density and 
confluence, thus resulting in the induction of differentiation under these 
conditions [189]. 
Hyaluronic acid (HA) is linear polysaccharide possessing a loose and 
highly hydrated matrix which functions in tissue homeostasis and affects the 
cellular phenotype. Even though it may be synthesized by 3 main synthases 
(HAS1, HAS2 and HAS3), HAS2 is the predominant isoform detected in cultured 
human aortic SMCs [31, 190]. HAS2 mRNA expression was measured because 
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this isoform is known to be highly expressed in vivo during SMC phenotypic 
changes that occur during the development of cardiovascular pathologies 
including atherosclerosis, neointimal hyperplasia and abdominal aneurysm 
development [74, 182, 183]. At each time point of analysis (Figure 4.1.2), there 
was significant increase in HAS2 mRNA expression in cells cultured under de-
differentiation-promoting conditions compared with differentiation–promoting 
conditions. Also, an inverse correlation between HAS2 and α-actin mRNA 
expression was observed (Figure 4.1.1), where the increase in α-actin was 
associated with a decrease in HAS2 expression. Thus, in addition to reduction in 
differentiation marker expression, HAS2 was utilized as the primary marker of de-
differentiation in these cells. 
As an alternative method of inducing differentiation, cells were cultured in 
de-differentiation-promoting media for 2 days and then serum-deprived over time. 
Under these conditions of serum-deprivation, a trend toward increased 
expression of α-actin and SM22α was observed, and these levels were 
significant from the 3-day time point up to the 5-day time point. Even though 
levels of both markers increased daily with serum-deprivation, an exponential 
increase in α-actin levels was observed over time, with up to a 50-fold increase 
after 5-days in serum deprivation media, compared to about a 3-fold increase in 
SM22α at the same time point. Therefore, similar to the cells cultured over time in 
differentiation-promoting media containing high levels of heparin, the serum 
deprivation method of inducing differentiation also determined that the 
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quantitation of α-actin expression was more effective than SM22α for identifying 
the differentiated phenotype.  
In summary, for subsequent experiments, hASMCs were cultured either in 
differentiation-promoting media, or under conditions of serum-deprivation to 
induce the differentiated phenotype in these cells. In addition, de-differentiation-
promoting media was used to induce the de-differentiated phenotype in cultured 
hASMCs. The observed increase in these markers of differentiation (α-actin 
and/or SM22α) in cultured cells was used to assess differentiation while 
decrease in these markers denoted reduced differentiation or de-differentiation. 
Furthermore, the significant increase in HAS2 expression was a characteristic of 
the synthetic phenotype in vitro. Even though the pattern of differentiation 
induction was similar between both differentiation markers, the fold increase in α-
actin protein expression over time was greater than that observed with SM22α. 
Since α-actin expression was consistently expressed in cells cultured under 
conditions promoting differentiation, and was exponentially greater than SM22α 
expression, α-actin was selected as the primary marker of differentiation in these 
hASMCs.  
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CHAPTER 5: ANGIOTENSIN II TREATMENT CONTRIBUTES TO REDUCED 
DIFFERENTIATION IN HUMAN AORTIC SMOOTH MUSCLE CELLS 
Introduction 
Vascular smooth muscle cells (SMCs) are crucial components of the 
vessel wall which are responsible for maintenance of structural and functional 
characteristics such as contraction and relaxation, remodeling and repair, growth 
and development within the blood vessel [191]. These functions may be 
regulated by local and systemic factors resulting in the promotion of physiological 
processes, or mediating pathological mechanisms in the development of vascular 
diseases. One of such factors is angiotensin II (AngII), which is a potent, 
vasoactive, multifunctional peptide synthesized from its precursor (angiotensin I) 
by the angiotensin converting enzyme (ACE). 
AngII is a pro-inflammatory mitogenic agent which has been demonstrated 
to regulate cell proliferation and apoptosis, influence cell migration and 
deposition of extracellular matrix within the vessel wall [191]. In in vitro vascular 
SMC culture models, AngII has been demonstrated to induce cell proliferation 
and migration, in part, by mediating an increase in mRNA and protein expression 
of the inducible cyclooxygenase enzyme (COX-2) [192, 193]. Alternatively, AngII 
treatment in vascular SMCs may also contribute to cell proliferation and survival 
by promoting release of proinflammatory cytokines such as IL-1β [194], inducing 
expression of growth-promoting factors such as IGFR-1 [195, 196] and PDGF-D 
[197] or by increasing gene expression of ROS and ET-1 in these cells [198]. All 
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these effects have been shown to be mediated by activation of numerous 
signaling pathways downstream of the Angiotensin II receptors [191]. 
Angiotensin II has also been reported to regulate the vascular SMC 
phenotype and contribute to vascular remodeling by regulating the expression of 
markers of both the contractile and synthetic phenotype, as well as altering the 
composition of extracellular matrix components. AT1 receptor activation by AngII 
has been demonstrated to induce mRNA expression of α-actin in vascular SMCs 
mediated partly by increased myocardin expression and SRF binding to CArG 
elements within the SM α-actin promoter [199]. Furthermore, AngII treatment in 
quiescent cells increased mRNA and protein expression of calponin also 
mediated by AT1 receptor activation [200, 201]. On the other hand, increase in 
osteopontin (synthetic marker) has been reported with AngII treatment in aortic 
SMCs [202]. Also, enhanced AngII signaling due to increased expression of ACE 
in miR-143/145 mutant mice is associated with a phenotypic shift in vascular 
SMCs from the contractile to the synthetic state [38]. These contrasting findings 
indicate that AngII stimulation is able to induce both differentiation and de-
differentiation in vascular SMCs cultured under different conditions by activating 
different downstream signaling pathways.  
In animal models of vascular disease, AngII treatment has been observed 
to contribute to disease pathology by mediating a phenotypic shift from the 
contractile to the synthetic phenotype in vascular SMCs. Medial hypertrophy of 
the aorta and coronary arteries in a model of AngII-induced hypertension in rats 
has been shown to be associated with increased expression of vascular SMC 
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synthetic markers, thus indicating a phenotypic shift to the immature de-
differentiated phenotype [203, 204]. Research findings in our lab utilizing an 
AngII-infused mouse model of abdominal aortic aneurysms (AAAs) have 
demonstrated that increased expression of COX-2 in vascular smooth muscle 
cells within the aneurysmal lesion may contribute to pathogenesis of this disease 
[71, 148]. Furthermore, COX-2 may contribute to the formation of AngII-induced 
AAAs by altering the differentiated phenotype, because COX-2 inhibition with 
celecoxib preserves the differentiated phenotype and limits progression of AAAs 
in mice [74]. In addition to COX-2 induction, the inducible microsomal synthase 
enzyme (mPGES-1) and prostaglandin E2 have been associated with the 
pathogenesis of this disease in the AngII-induced mouse model [128, 205]. 
These findings suggest that AngII may promote the pathogenesis of AAAs by the 
induction of specific products of the prostanoid synthetic pathway. 
In humans, aortic SMCs located within the aneurysmal lesion have been 
shown to exhibit reduced expression of SMC markers of differentiation compared 
to normal aorta [53]. In addition, there is increased expression of COX-2 and 
microsomal prostaglandin E2 synthase (mPGES-1), and explant tissue obtained 
from human AAA biopsies produce increased levels of prostaglandin E2 (PGE2) 
[147, 150, 151]. Due to the potential contribution of AngII to the disease 
pathology in humans, clinical studies have proposed that inhibition of AngII 
production resulting from treatment with ACE inhibitors may be beneficial in 
treating AAAs in humans [206-208]. 
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Therefore, based on results showing increased expression of COX-2 and 
mPGES-1 during development of AAAs [147, 150, 151, 209, 210] as well as 
reports associating AngII with alteration of the vascular SMC phenotype [199-
201], the hypothesis that treatment of vascular SMCs with AngII in vitro will 
induce expression of COX-2 and mPGES-1, while reducing differentiation in 
these cells was proposed. In order to test this, human aortic smooth muscle cells 
(hASMCs) were cultured under different conditions and the cells were treated 
with varying concentrations of AngII over time. The effect of AngII treatment on 
the cell phenotype was studied by measuring protein levels of the markers of 
differentiation, α-actin and/or SM22α. In addition, the expression of COX-2 and 
mPGES-1 were also measured in order to examine the potential effect of AngII 
treatment on the expression of these. 
 
Results 
5.1 Effect on α-actin expression from treatment of differentiated hASMCs 
with angiotensin II under conditions promoting differentiation.  
Cells cultured under conditions promoting differentiation are induced to 
differentiate evidenced by the expression of higher levels α-actin over time (see 
Figure 4.1.1). I hypothesized that treatment of hASMCs with AngII under 
differentiation-promoting conditions would reverse differentiation by significantly 
reducing the expression levels of markers of differentiation in these cells. To 
investigate the role of AngII in the modulation of the differentiated SMC 
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phenotype, hASMCs were cultured under conditions promoting differentiation for 
two days and thus induced to differentiate. The cells were subsequently treated 
with 0.1, 0.5, or 1 µM concentrations of AngII for either 1 or 2 days under these 
same conditions. Control cells were treated with 0.1% PBS for the same time 
period. Cells were lysed, harvested at each time point, and then analyzed for 
protein levels of α-actin via western blotting. 
Treatment with AngII for 1 day did not result in reduction in levels of α-
actin (Figure 5.1A). However, at the 2-day time point, a trend toward reduction in 
differentiation was observed, demonstrated by lower levels of α-actin in AngII 
treated cells compared with controls (Figure 5.1B).  
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promote the reduction in α-actin levels in AngII-treated cells compared with 
vehicle-treated controls.   
Cells were plated for 2 days in differentiation promoting media and then 
treated with either 0.1 or 0.5 µM of AngII in growth-promoting media for 1 or 2 
days. Control cells were treated with vehicle for the same time period. Cells were 
lysed, harvested at each time point, and analyzed for protein levels of α-actin via 
western blotting. 
The lower concentration of AngII (0.1 µM) trended towards increasing α-
actin expression whereas the higher concentration (0.5 µM) consistently reduced 
α-actin expression in these cells at each time point (Figure 5.2 A & B). Treatment 
with 0.1 µM AngII trended toward increase in α-actin levels while 0.5 µM showed 
reduction compared with vehicle-treated controls. 
Since there was a trend toward reduction in α-actin expression with 0.5 
µM AngII treatment, differentiated cells were treated daily with either 0.5 µM or 
1.0 µM AngII over a longer time period (1 to 4 days) under de-differentiation-
promoting conditions, and the effect on α-actin protein levels was examined via 
immunocytochemistry. Treatment for either 1 or 2 days did not result in 
significant reduction in α-actin expression (Figure 5.2 C&D). However, by the 3rd 
day, significant reduction in α-actin levels was observed with 1.0 µM AngII 
treatment. Furthermore, both 0.5 and 1.0 µM AngII treatments resulted in 
significant reduction in α-actin protein levels compared to vehicle-treated cells by 
the 4th day of treatment (Figure 5.2 E&F).  
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Figure 5.2 (continued)
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5.3 Reduced α-actin levels in differentiated hASMCs treated with AngII 
under de-differentiation-promoting conditions is associated with increased 
mPGES-1 expression but not COX-2 expression  
With the observation of a trend toward reduction in α-actin protein levels 
when differentiated cells were treated with 0.5 µM AngII under conditions 
promoting de-differentiation, protein expression levels of mPGES-1 and COX-2 
at this concentration of AngII were subsequently examined. Cells were cultured 
under differentiation-promoting conditions and then treated with 0.5 µM AngII 
under conditions promoting de-differentiation for either 1 or 2 days. Control cells 
were treated with the vehicle (0.1% PBS) for the same time period. At each time 
point, cells were lysed and harvested and protein levels of COX-2 and mPGES-1 
were examined via western blotting. 
Treatment with 0.5 µM AngII did not affect COX-2 expression at either the 
1 or 2 day time points. However, at the 2-day time point, there was significant 
increase in mPGES-1 protein levels.  
In addition, protein levels of α-actin in these cells pursuant to mPGES-1 
induction by AngII treatment, was subsequently examined. To do this, cells were 
differentiated as above and then treated with 0.5 µM AngII under de-
differentiation-promoting conditions for 3 days. At the 3-day time point, cells were 
fixed and analyzed for α-actin protein levels via immunocytochemistry. Significant 
decrease in α-actin protein levels was observed in 0.5 µM AngII treated cells 
compared with vehicle-treated controls. 
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cultured under growth promoting conditions for 2 days and then the media was 
changed to serum-free media. AngII treatment was initiated at different time 
points during the serum-starvation period. 
5.4.1 Effect on α-actin expression from the initiation of AngII treatment at 
the beginning of serum-deprivation  
After culturing cells in growth promoting media for 2 days, the cell media 
was changed to serum-free media. At the 2 day time point in which cell media 
was changed to serum-deprived media, 0.5 µM or 1 µM AngII in serum-free 
media was added to these cells and incubated for 4 days. Vehicle-treated 
controls were incubated in 0.1% PBS in serum-free media. Cells were lysed and 
harvested each day over the four days and analyzed for α-actin expression via 
western blotting.  
AngII treatment of growing cells under serum-deprivation conditions 
trended towards increase in α-actin protein levels (Figure 5.4.1). These results 
indicated that AngII treatment did not reduce α-actin expression in treated cells at 
either time point. Instead, there was an unexpected trend toward increase in α-
actin expression in the AngII treated cells and this was significant at with 0.5 µM 
AngII treatment at the 2 day time point.  
Figure 5.4.1 Effect on α-actin expression from the initiation of AngII 
treatment at the beginning of serum-deprivation  
Densitometry and representative western blots showing protein levels of α-actin 
in growing cells treated for (A) 1, (B) 2, (C) 3, or (D) 4 days with 0.5 µM or 1.0 µM 
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5.4.2 Effect on α-actin expression from the initiation of AngII treatment after 
2 days of serum-deprivation  
As observed from preliminary data, after 2 days in serum starved media, 
hASMCs begin to commence the process of differentiation by expressing 
increasing levels of markers of differentiation (see Figure 4.2). I hypothesized 
that AngII treatment of cells at this 2 day time point under these conditions over 
time will result in inhibition of differentiation evidenced by significant reduction in 
expression levels of markers of differentiation. To test this hypothesis, hASMCs 
were cultured under growing conditions for 2 days and then the cell media was 
changed to serum-free media for two days. Next, either 0.5 or 1.0 µM of AngII 
was added into this cell culture media for between 1 to 3 days. Control wells 
were treated with vehicle (0.1% PBS). At each time point, cells were lysed and 
harvested for α-actin and SM22α protein levels via western blotting. 
Treatment with AngII did not result in significant reduction in α-actin 
protein levels at each time point examined. Even though there was a trend 
toward decrease in SM22α levels after 1 day of treatment, this reduction however 
was not consistent over the 2 or 3 day time points (Figure 5.5.2). 
Figure 5.4.2 Effect on α-actin expression from the initiation of AngII 
treatment after 2 days of serum-deprivation  
Densitometry and representative western blots showing protein levels of (A) α-
actin, or (B) SM22α in growing cells treated for 1, 2, or 3 days with 0.5 µM or 1.0 
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5.4.3 Effect on α-actin expression from the initiation of AngII treatment after 
3 days of serum-deprivation  
As observed from preliminary data, hASMCs cultured initially under 
growth-promoting conditions and then switched to serum-free media are induced 
to differentiate during the serum-deprivation over time (See Fig 4.2). At the 3-day 
time-point of serum-deprivation, significant increase in the levels of differentiation 
markers was observed up till the 5-day time point. I hypothesized that treatment 
of cells with AngII at this 3 day time-point over time will reverse differentiation in 
these cells evidenced by reduced expression levels of differentiation markers.  
To test this hypothesis, hASMCs were cultured under growing conditions 
for 2 days and then the cell media was changed to serum-free media for 3 days. 
At the 3-day time point, either 0.5 or 1.0 µM of AngII was added into this cell 
culture media for 1 or 2 days. Control cells were treated with 0.1% PBS for the 
same duration. 
The results showed that AngII treatment had no significant effect on the 
reduction of differentiation in treated cells compared with vehicle-treated controls 
(Figure 5.4.3).  
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certain cardiovascular diseases [212]. AngII signaling through the AT1 receptor 
has been shown to contribute to the known physiological effects of AngII in adult 
humans [213]. Under physiological conditions, ACE expression in the vasculature 
is low [38]. However, signaling due to aberrant activity of AngII within the 
vasculature may result in increased cardiac dysfunction and development of 
diseases [212, 214].  
Various animal models have been used to demonstrate pathological 
effects of abnormal AngII signaling within the cardiovascular system. Chronic 
AngII infusion in animal models has been shown to increase the luminal diameter 
of the aorta, and systolic blood pressure, and induce the formation of aortic 
aneurysms in mice [215, 216]. Therefore, clinical studies have proposed that 
inhibition of Angiotensin II production by ACE inhibitors may be beneficial in 
treating AAAs in humans [206-208]. 
AngII-induced thoracic or abdominal aortic aneurysm formation in animal 
models has also been shown to be associated with the reduced expression of 
differentiation markers in the vascular SMCs of the aneurysmal lesion [217]. 
Research in our lab has also reported increased COX-2 expression, reduced 
differentiation marker mRNA expression, and increased expression of a marker 
of de-differentiation in SMCs of aneurysmal lesions in AngII-induced AAAs in 
mice. The effectiveness of celecoxib (COX-2 inhibitor) in treating this disease 
was associated with maintenance of a differentiated phenotype in these cells 
[74]. Based on these findings, together with the research showing that 
transformation of vascular SMCs from the contractile to the synthetic phenotype 
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is associated with an increase in AngII production [218], I proposed that 
treatment of hASMCs with AngII would increase expression of COX-2 and 
mPGES-1, and reduce differentiation. 
To study the AngII effects on the hASMC phenotype in vitro, cells were 
induced to differentiate and then treated with AngII at various stages of the 
differentiation process, as well as under different culture media conditions. 
Treatment of differentiated hASMCs with AngII under conditions promoting 
differentiation resulted in a non-significant trend toward a reduction in 
differentiation evidenced by reduced levels of α-actin over time (Figure 5.1) 
Treatment with AngII under de-differentiation-promoting conditions also 
demonstrated a trend toward reduction in differentiation especially at the 0.5 µM 
concentration. However, 0.1 µM AngII treatment resulted in a trend toward 
increase in α-actin expression at both 1 and 2 day time point. Next, the effect on 
α-actin protein levels, of daily treatment of differentiated cells with increased 
AngII concentrations over a longer time frame under de-differentiation-promoting 
conditions, was investigated via immunocytochemistry. Though there was no 
significant difference in α-actin protein levels after the first 2 days of treatment, 
treatment with either 0.5 µM or 1.0 µM AngII however resulted in significant 
reduction in α-actin expression both at the 3 and 4 day time points (Figure 5.2 E 
& F). 
Furthermore, the effect of AngII treatment on the expression of mPGES-1 
and COX-2 was examined. Treatment with 0.5 µM AngII under conditions 
promoting de-differentiation resulted in significant induction of mPGES-1 protein 
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levels after treatment for 2 days. There was however no significant increase in 
COX-2 expression levels with AngII treatment for either 1 or 2 days AngII (Figure 
5.3). These findings were quite unexpected since in vitro SMC culture models 
indicate that AngII treatment increases COX-2 expression in vascular SMCs. 
The induction of COX-2 expression due to AngII stimulation may be an 
early event in cultured vascular SMCs. AngII treatment in rat vascular SMCs was 
shown to significantly increase COX-2 mRNA expression after treatment for 1 
hour and increase COX-2 protein levels after 4 hours. In this study, at the 24 
hour time point, the COX-2 expression had returned to basal states [192]. Also, 
Frias et al (2003) observed significant increase in COX-2 levels in rat aortic 
smooth muscle cells following a 0.5 to 4 hour incubation with AngII [219]. 
Similarly, AngII treatment in vascular SMCs induced COX-2 mRNA 
accumulation, commenced 30 minutes after stimulation and increased up to 2 
hours but had diminished greatly by 6 hours after AngII challenge [78]. 
Furthermore, these authors observed maximal induction of protein levels of COX-
2 after 4 hours of stimulation with AngII after which COX-2 protein levels 
subsequently reduced over a 48 hour time period. Thus, there may have been no 
observable increase in COX-2 expression with AngII treatment in our studies due 
to the fact that these cells were analyzed for COX-2 protein levels after much 
longer AngII-treatment periods (24 to 48 hours), during which COX-2 expression 
had probably returned to basal states. It is probable that harvesting AngII-treated 
cells at earlier time points in this study may have demonstrated significant 
increase in COX-2 protein in these cells.  
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Alternatively, the lack of induction of COX-2 protein may be because in 
our studies, cells were treated with AngII under conditions promoting de-
differentiation. This may have resulted in maximal induction of COX-2 such that it 
was no longer possible to induce COX-2 production with AngII treatment under 
these conditions. The increased presence of serum and growth factors has been 
shown to contribute to the expression of COX-2 in cells [220-223]. Since the 
induction of COX-2 previously observed in various in vitro models was observed 
in confluent quiescent cells SMCs [78, 192] which were stimulated with AngII in 
the absence of serum and for shorter periods of time, this major difference in 
treatment conditions may have further inhibited induction of COX-2 protein. 
It is interesting to note also that significant reduction in α-actin levels did 
not occur in differentiated cells treated with AngII under de-differentiated-
promoting conditions for 1 to 3 days (Figure 5.2). Only at the 4-day time point 
was there significant reduction in α-actin protein levels in these cells. This 
reduction occurred after the significant induction of mPGES-1 expression at the 2 
day time point suggesting that the reduction in differentiation marker expression 
with AngII treatment may not occur early, but subsequent to the induction of 
mPGES-1 levels (Figure 5.3). 
The effect of AngII treatment on the induction of differentiation via serum-
deprivation was subsequently examined. Serum-deprivation promotes the 
differentiated state in vascular SMCs by inducing the expression of markers of 
differentiation. Furthermore, serum-deprivation provides a suitable condition in 
which we can examine the effect of AngII treatment without the potential for 
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interaction with serum-containing components. Regardless of the time point of 
AngII administration during the process of serum-deprivation, AngII treatment did 
not significantly reduce the expression of protein levels of α-actin or SM22α in 
these cells (Figure 5.4). In fact, there was a trend toward increase in the protein 
levels of differentiation markers in AngII-treated cells over time. These findings 
suggest that AngII may not induce reversal of differentiating cells to the synthetic 
phenotype in these hASMCs.  
The absence of a suitable mitogenic trigger for the activation of 
pathological AngII signaling may be a major factor why there was no significant 
decrease in α-actin levels in serum-deprived hASMCs treated with AngII under 
the same conditions. AngII treatment under de-differentiation-promoting 
conditions introduces a variety of growth factors to the cell media which may 
provide the suitable milieu for AngII activity and signaling [212]. Thus, AngII 
treatment under conditions of serum-deprivation conditions may not have 
significantly reduced the expression of differentiation markers in these cells due 
to the absence of these mitogenic cues.  
Furthermore, even though AngII treatment in confluent quiescent cells 
under conditions of serum-starvation has been shown to induce the expression of 
COX-2 in cells, this effect has been associated with the induction of cell 
proliferation [78, 192], not differentiation. Since COX-2 protein was not measured 
under these conditions, it is difficult to ascertain if COX-2 levels were upregulated 
with AngII treatment under these conditions of serum-deprivation. Regardless of 
the COX-2 expression profile under these conditions, there was a trend toward 
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an increase in differentiation with AngII treatment (Figure 5.4.1). AngII-mediated 
increase in differentiation markers has been reported by other investigators. The 
increase in α-actin gene transcription, as well as calponin mRNA expression and 
protein levels, has been observed previously following treatment of cultured 
vascular SMCs with AngII [199-201].  
The ability of AngII to regulate the vascular SMC phenotype would depend 
on AngII receptor expression in the cells. AT1 receptors are abundantly 
expressed in cultured vascular SMCs and activation of this receptor by AngII 
mediates the growth-promoting effects. The AT2 receptor however is expressed 
in early development and in during vascular injury [201]. Reduced expression of 
in AT1 and AT2 receptor was observed in passage-dependent manner with older 
passages showing reduced expression of these receptors. Heparin treatment 
however recovered expression of these receptors in the later passages and 
increased expression of vascular SMC markers of differentiation [168]. Sabri et al 
(1997) demonstrated that the reduction of SMC differentiation and elevation of 
blood pressure in a mouse model of AngII induced hypertension was due to 
activation of the AT1 receptor [203]. Conversely, Yamada et al (1999) 
demonstrated that AngII activation of the AT2 receptor enhances differentiation of 
aortic SMCs [224]. In these studies, the receptor expression pattern of the AngII 
receptor was not examined thus cannot attest to their presence or absence in 
hASMCs cultured under different conditions. Therefore, the effectiveness of AngII 
treatment under these conditions may have resulted from increased expression 
of the AT1 receptor.  
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Angiotensin II may also be synthesized endogenously by the vascular 
SMCs [225]. Fibronectin is an extracellular matrix glycoprotein which contributes 
to vascular SMC migration, growth and phenotypic modulation. Upon phenotypic 
switch from the contractile to the synthetic phenotype induced by fibronectin, 
vascular and human aortic SMCs have been demonstrated to produce increased 
levels of AngII, thus contributing to increased proliferation of SMCs [218, 226]. 
Furthermore, endogenous AngII synthesis was increased in vascular SMCs 
obtained from spontaneously hypertensive rats compared with normotensive 
ones, and this increase was associated with increased DNA synthesis, 
production of growth factors, and decreased expression of differentiation markers 
in these cells [227, 228]. Endogenous concentrations of AngII produced in these 
hASMCs cultured under different conditions were not measured, but current 
research indicates that endogenous AngII production increases during a shift 
from the contractile to the synthetic phenotype in hASMCs [218]. However, the 
treatment of differentiated cells with AngII under conditions promoting de-
differentiation may have potentiated the actions of the endogenous AngII or other 
factors contributing to reduction in differentiation, thereby resulting in the 
observed decrease in α-actin expression (Figure 5.3). 
In conclusion, AngII stimulation of differentiated hASMCs in vitro may 
promote de-differentiation by the induction of mPGES-1 expression in these 
cells. Increased mPGES-1 synthesis results in increased production of 
prostaglandin E2 (PGE2) and this is the principal prostanoid secreted in pro-
inflammatory conditions. However, there was considerable variability of response 
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observed with AngII treatment in these cells, with AngII acting to either reduce or 
increase expression of markers of differentiation under different cell culture and 
treatment conditions. Only with treatment of differentiated cells with AngII under 
conditions promoting de-differentiation was there a significant reduction in α-actin 
levels. Therefore, in order to further investigate the mechanisms responsible for 
the reduced differentiation of hASMCs observed with AngII treatment, the 
contributions of COX-2, mPGES-1, and PGE2 (products of the prostanoid 
synthesis pathway) observed to be upregulated in AAA disease models, were 
subsequently examined. 
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CHAPTER 6: PHARMACOLOGICAL INHIBITION OF COX-2 by CELECOXIB 
PROMOTES DIFFERENTIATION IN HUMAN AORTIC SMOOTH MUSCLE 
CELLS 
Introduction 
The cyclooxygenase (COX) enzymes catalyze the rate-limiting step in the 
biosynthesis of prostanoids. Two isoforms of the COX enzyme exist: COX-1, 
which is the constitutive enzyme, and COX-2, which is the inducible form. The 
COX-1 enzyme is primarily associated with “housekeeping” functions in normal 
tissues such as hemostatic, gastric protection, and renal water balance [63, 79]. 
However, in response to stress, cytokines, growth factor stimulation, and 
inflammatory stimuli, COX-2 expression increases [79]. The COX enzymes 
convert arachidonic acid first into prostaglandin G2 (PGG2) via oxygenation, and 
then to prostaglandin H2 (PGH2) via peroxidase activity. PGH2 is subsequently 
converted by tissue specific synthases into different prostanoids including 
prostacyclin (PGI2), prostaglandin E2 (PGE2), prostaglandin D2 (PGD2), 
thromboxane (TXA2), and prostaglandin F2α (PGF2α) [80, 81]. These prostanoids 
exert their actions by activating and signaling through their individual receptors. 
Thus, the biological actions of these prostanoids may be modulated at the level 
of the cyclooxygenase enzymes, individual synthases or the prostanoid receptors 
[84].  
Increased expression of the inducible cyclooxygenase enzyme (COX-2) 
has been implicated in the pathogenesis of numerous diseases including cancer, 
84 
 
atherosclerosis, osteoarthritis, and aneurysms [149, 229-233]. More specifically, 
during the development of abdominal aortic aneurysms (AAAs), recent research 
in animal models, as well as human aneurysmal biopsies, has implicated the 
COX-2 enzyme in the pathogenesis of this disease. In AngII-induced mouse 
models of AAAs, increased expression of COX-2 is observed in SMCs of the 
aortic aneurysmal lesions compared with normal aorta [148, 150]. The, genetic 
deletion of this COX-2 enzyme has been demonstrated to significantly reduce the 
incidence and severity of this disease in animal models [148]. In addition, 
pharmacological inhibition of COX-2 with celecoxib is effective in reducing the 
incidence, severity, and progression of this disease in murine models [75, 205]. 
Similarly, in human biopsy explants from AAA lesions, the increase in COX-2 
expression has been observed when compared to normal, uninvolved aorta [147, 
149, 234].  
Aside from the involvement of COX-2 during development of this disease, 
alteration of the vascular SMC phenotype has also been observed in the 
developing aneurysm in both human biopsies and animal models of AAAs. 
Ailawadi et al (2009) observed significant downregulation of markers of 
differentiation in the SMCs of aneurysmal lesions, compared with the uninvolved 
aorta both in human biopsy specimens, as well as an animal model of this 
disease [53]. In an AngII-induced animal model of AAAs, reduction in 
differentiation demonstrated by decreased expression of markers of 
differentiation and increased expression of markers of de-differentiation are also 
observed in the aneurysmal lesion, compared with normal uninvolved aorta. In 
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the AngII-induced AAA mouse model, pharmacological inhibition of the COX-2 
enzyme with celecoxib is associated with preservation of the differentiated 
vascular SMC phenotype [74]. Therefore, the hypothesis that increased 
expression of COX-2 will promote reduced differentiation in hASMCs and that 
pharmacological inhibition of COX-2 in vitro will be effective in promoting hASMC 
differentiation was proposed. 
 
Results 
6.1 Characterization of cyclooxygenase-2 (COX-2) expression in hASMCs  
6.1.1 Increased hASMC differentiation over time correlates with decreased 
COX-2 expression.  
The expression of COX-2 in cultured hASMCs was examined and 
correlated with differentiation marker expression both at the mRNA and protein 
levels. Cells were cultured under either de-differentiation-promoting (d-DC) or 
differentiation-promoting conditions (DC) over a period of 4 days for analysis of 
mRNA and for a period of 5 days for protein analysis. Samples were harvested 
after every 24 hours and analyzed via real-time PCR for mRNA and western 
blotting for protein.  
Significant reduction in COX-2 mRNA expression in cells cultured under 
differentiation-promoting conditions compared with cells cultured under de-
differentiation-promoting conditions at each time point was observed (Figure 
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6.1.1A). A similar result was also observed in the protein levels of COX-2 at each 
time point, with cells cultured in de-differentiation-promoting media demonstrating 
greater levels of COX-2 compared with cells in differentiation-promoting media 
(Figure 6.1.1C). This COX-2 expression was correlated with that of α-actin and 
an inverse relationship between both their mRNA expression and protein levels 
was observed. Cells cultured under differentiating-promoting conditions 
expressed significantly higher levels of α-actin mRNA and protein compared with 
COX-2 at each time point (Figure 6.1.1B & C)). These results indicate that COX-
2 expressing hASMCs show reduced expression of differentiation markers.  
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Figure 6.1.1 Increased hASMC differentiation over time correlates with 
decreased COX-2 expression.  
mRNA expression of (A) COX-2 and (B) α-actin in hASMCs cultured for 1 to 4 
days under conditions promoting differentiation or de-differentiation. (C) 
Representative western blot showing protein levels of COX-2 and α-actin, and 
SM22α, with α-tubulin as loading control, in hASMCs cultured for 1 to 5 days 
under conditions promoting differentiation or growth. Data represents mean + 
SEM (n≥3), **** = p < 0.0001, unpaired Student’s t test comparing expression 
levels between differentiation conditions (DC) and growth conditions (d-DC) at 
each individual time point.  
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under conditions promoting de-differentiation demonstrated significantly 
increased COX-2 expression compared with differentiation-promoting media, the 
hypothesis that serum-deprivation would reduce expression of COX-2 while 
increasing differentiation in these cells was proposed. The levels of COX-2 
protein in serum-deprived cells were examined and then correlated with hASMC 
differentiation. To do this, cells were cultured under de-differentiation-promoting 
conditions for 2 days and then the media was changed to serum-free media for 5 
days. Cells were lysed and harvested daily and subsequently analyzed for 
protein levels of COX-2 and the markers of differentiation, α-actin and SM22α, 
via western blotting. 
Cells cultured for 2 days under de-differentiation-promoting conditions 
expressed increased COX-2 protein levels compared with conditions of serum-
deprivation. By the first day of serum-deprivation, the COX-2 protein levels were 
drastically reduced compared with the control, and the COX-2 protein levels 
continually reduced over time till it was undetectable (Figure 6.1.2A). However, 
as observed previously (Figure 4.2), serum deprivation resulted in an increase in 
α-actin and SM22α protein levels, thus indicating the increased differentiation of 
the cells.  
The induction of COX-2 expression that occurs in response to de-
differentiation-promoting media in cells that were previously serum deprived was 
also examined. The re-stimulation of serum-deprived cells with de-differentiation-
promoting media increased COX-2 protein levels for the first 2 days, which then 
declined by the third and fourth days (Figure 6.1.2B). 
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6.2 Effect of COX-2 inhibition by celecoxib on hASMC phenotypic 
modulation.  
6.2.1 COX-2 inhibition by celecoxib increases α-actin levels in hASMCs 
cultured under differentiation-promoting conditions.  
The effect of cyclooxygenase 2 (COX-2) inhibition by celecoxib on the 
hASMC phenotype in vitro was investigated. Since hASMC cultured under 
conditions promoting either de-differentiation or differentiation do express COX-2, 
albeit at varying levels, hASMCs were treated with celecoxib under both 
conditions. For treatment with celecoxib under reduced levels of COX-2 
expression, cells were cultured under differentiation-promoting conditions. The 
cells were cultured for 2 days in differentiation-promoting media, and then treated 
with either 2, 5 or 10 µM celecoxib for 1, 2 or 3 days. Non drug-treated controls 
were incubated with media containing the vehicle (0.1% DMSO). At each time 
point, cells were lysed, harvested and analyzed for α-actin protein levels via 
western blotting.  
A trend toward increase in α-actin protein levels in the celecoxib-treated 
cells compared with untreated controls was observed. Although there was a 
trend for increased α-actin expression following treatment with 5 µM celecoxib for 
1 or 2 days, the change was not statistically significant (Figure 6.2.1). At the 2 
and 3 day time points, cells treated with 10 µM celecoxib showed significantly 
increased α-actin levels compared with vehicle-treated controls. 
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6.2.2 COX-2 inhibition increases α-actin levels in hASMCs cultured under 
conditions promoting de-differentiation.  
Upon observing increased levels of α-actin in celecoxib-treated cells under 
conditions promoting differentiation, the effect of celecoxib on cells cultured 
under de-differentiation-promoting conditions in which higher expression of COX-
2 was observed was examined. Cells were cultured under de-differentiation-
promoting conditions for 2 days and then treated with 2, 5, or 10 µM celecoxib for 
either 1 day or 2 days. At each time point, cells were fixed and analyzed for α-
actin levels via immunocytochemistry.  
Significant increase in α-actin levels in cells treated with 2 µM celecoxib at 
the 1 day time point was observed (Figure 6.2.2A). However, treatment with 
either 5 µM or 10 µM of celecoxib at the 1 day time point did not result in a 
statistically significant increase in α-actin expression compared to vehicle-treated 
controls. In addition, there were no significant differences in α-actin expression 
with any of the treatment concentrations after 2 days of treatment (Figure 
6.2.2B).  
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 Figure 6.2.2 COX-2 inhibition increases α-actin levels in hASMCs cultured 
under conditions promoting de-differentiation.  
Densitometry quantitation of α-actin expression in differentiated cells treated with 
celecoxib under de-differentiation-promoting conditions for (A) 1 day or (B) 2 
days. Data represents mean + SEM (n=3), * = p < 0.05; one-way ANOVA and 
post hoc analysis with Dunnett’s Multiple Comparison test.  
*
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6.2.3 Treatment with celecoxib under serum-deprivation conditions inhibits 
the induction of differentiation in hASMCs.  
Previous results had shown that increased differentiation observed in 
serum-deprived hASMC is associated with reduced expression of COX-2 (Figure 
6.1.2A). The increase in differentiation was observed to begin after 2 days of 
serum-deprivation and the continued increase correlated with the number of days 
the cells were in serum-free media. Since, serum deprivation induces 
differentiation in these cells, and reduced COX-2 levels were observed under 
these conditions, it was hypothesized that treatment of hASMCs with celecoxib 
under conditions of serum-deprivation would inhibit any remaining COX-2 that 
was expressed during the progression of differentiation thereby potentiating the 
induction of differentiation under these conditions. The effect of COX-2 inhibition 
at the beginning of serum-deprivation on the induction of differentiation marker 
expression in these cells was examined. Cells were cultured for 2 days in de-
differentiation-promoting media and then treated at the beginning of serum-
withdrawal with either 2, 5, or 10 µM of celecoxib for between 1, 2, or 3 days. 
Cells were harvested each day and then analyzed for α-actin and SM22α protein 
levels via western blotting.  
Under conditions of serum deprivation, it was observed that celecoxib 
treatment did not enhance differentiation in these cells as there was no 
significant increase in either α-actin or SM22α protein levels at any of the time 
points examined. In fact, by the third day of celecoxib treatment, there was 
significant reduction in the protein levels of both markers of differentiation. 
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2 by celecoxib under conditions of serum-re-stimulation will induce differentiation 
in hASMCs was proposed. To test this hypothesis, cells were cultured for 2 days 
under de-differentiation-promoting conditions, and then quiesced overnight by 
serum-deprivation. Next, cells were re-stimulated for 1, 2 or 3 days with de-
differentiation-promoting media containing vehicle, 2, 5, or 10 µM celecoxib. 
hASMCs were lysed and harvested at each time point and analyzed for protein 
levels of α-actin, SM22α and COX-2 via western blotting.  
After one day of celecoxib treatment under re-stimulated conditions, there 
was a slight trend toward an increase in α-actin and SM22α protein levels in 
celecoxib treated cells, compared with vehicle-treated controls. After 2 days of 
treatment, the 5µM celecoxib concentration was significant for SM22α but not α-
actin expression. COX-2 protein levels however began to trend toward reduction 
after 1 day treatment and this decrease was significant at all concentrations by 
the 2 day time point. In contrast, treatment with 2, 5, or 10 µM celecoxib for 3 
days under conditions of re-stimulation resulted in significant reduction of α-actin 
and COX-2 expression at all 3 celecoxib concentrations, and a significant 
reduction of SM22α at the 10 µM celecoxib treatment (Figure 6.2.4).  
Figure 6.2.4. Inhibition of COX-2 by celecoxib under serum-stimulated 
conditions reduces hASMC differentiation over time. 
Representative western blot and densitometry quantitation of (A) α-actin and (B) 
SM22α in growing cells treated with either 2, 5, or 10 µM of celecoxib under 
serum-stimulated conditions for 1 day, 2 days, or 3 days. Data represents mean 
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preservation of the differentiated SMC phenotype [74]. In order to characterize 
the potential role of COX-2 in regulating vascular SMC differentiation, the 
expression of the COX-2 enzyme under different cell culture conditions was 
examined and correlated with the expression of markers of hASMC differentiation 
(α-actin and/or SM22α). Subsequently, the effects of pharmacological inhibition 
of COX-2 by celecoxib on the hASMC phenotype under conditions of increased 
or decreased COX-2 expression were investigated. 
An inverse correlation between COX-2 and differentiation marker 
expression was observed in these cultured hASMCs. Increase in hASMC 
differentiation induced either by differentiation-promoting media (Figure 6.1.1) or 
serum-deprivation (Figure 6.1.2A) was associated with reduced COX-2 
expression. However, COX-2 expression was significantly increased in cells 
cultured under growth-promoting conditions, compared to cells cultured under 
differentiation-promoting conditions, at each time point (Figure 6.1.1). In addition, 
re-stimulation of serum-deprived cells induced expression of COX-2 after serum 
deprivation for 1 or 2 days (Figure 6.1.2B). Thus, incubation of hASMCs in media 
containing growth-promoting agents including increased serum and growth 
factors is associated with the induction of COX-2 mRNA and protein expression. 
In addition, based on the differentiation state of these cells, differing levels of 
COX-2 expression in these hASMCs was observed regardless of the cell culture 
conditions.  
Cell stimulation by media containing serum and/or growth factors has 
been demonstrated to induce the expression of COX-2 in a variety of cell types 
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including vascular SMCs [220-223]. Under growth-promoting conditions, cells are 
cultured in media containing increased serum (about 5% FBS) and a variety of 
growth factors, thus resulting in increased transcription and translation of COX-2 
in these cells compared with cells cultured under differentiation-promoting 
conditions. Removal of these stimulants (serum and growth factors) during 
serum-deprivation however, resulted in the significant reduction in COX-2 
expression, with protein levels measured under this condition becoming greatly 
reduced over time. Furthermore, serum and growth factors have been shown to 
trigger activation of vascular SMCs to the synthetic phenotype [174]. Conversely, 
with the induction of differentiation in serum-deprived cells, significant reduction 
in COX-2 protein levels over time was observed. 
To further understand the mechanisms by which COX-2 may regulate the 
cells phenotype the effects of pharmacological inhibition of COX-2 by celecoxib 
on cell differentiation under conditions of increased or decreased COX-2 
expression was examined. Celecoxib treatment of differentiating cells further 
promoted differentiation in both a time and dose- dependent manner (Figure 
6.2.1), whereas with cells cultured under conditions promoting de-differentiation, 
celecoxib induced differentiation only at the lowest concentration (Figure 6.2.1). 
Since culturing cells under de-differentiation-promoting conditions greatly induces 
COX-2 expression, it was expected that a higher treatment concentration of 
celecoxib of 10 µM would be required to inhibit COX-2 sufficiently to promote 
differentiation, similar to that observed in the differentiated cells. However, it was 
surprising to observe that the lowest celecoxib concentration used (2 µM) 
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promoted a significant increase in α-actin after treatment for 1 day, whereas, the 
highest concentration of 10 µM trended toward a reduction in α-actin levels over 
time. The 2 µM celecoxib treatment was proposed to provide more specific 
inhibition of COX-2 than either the 5 or 10 µM concentrations under these 
conditions thereby resulting in the observed increase in α-actin expression in 
these cells. 
Previous reports have shown that serum-deprivation over time induces the 
expression of differentiation markers in vascular SMCs [23, 173, 174] and our 
current findings show that this condition is associated with reduced expression of 
COX-2, the levels of which become undetectable over time (Figure 6.1.2). Based 
on this finding, it was proposed that since reduced expression of COX-2 is 
associated with increased expression of differentiation markers, then inhibition of 
COX-2 by celecoxib under these conditions would promote the early induction of 
differentiation. At the initiation of serum-deprivation, the expression of COX-2 in 
these cells is significantly reduced but there was no significant increase in α-actin 
expression until the 3rd day of serum-deprivation (Figure 6.1.2A). In order to 
investigate if inhibition of COX-2 will induce differentiation in treated cells before 
the 3-day time point, hASMCs were treated with 2, 5 or 10 µM celecoxib under 
conditions of serum-deprivation over time. Celecoxib treatment however, did not 
induce differentiation marker expression in these cells (Figure 6.2.3). On the 
contrary, COX-2 inhibition by celecoxib under conditions of serum-deprivation 
over time was observed to reduce expression of α-actin and SM22α and this 
reduction was significant by the 3rd day of celecoxib treatment. 
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In general, it is expected that cell treatment with pharmacological agents 
in conditions of serum-free media provides the opportunity to explore effects of 
these agents on hASMC differentiation without the potential for interaction with 
constituents in the serum. The observation of de-differentiation in cells treated 
with celecoxib under conditions of serum-deprivation is potentially due to multiple 
factors. First, celecoxib is a molecule which significantly binds to albumin. 
Studies analyzing protein binding in serum have shown that approximately 97% 
of celecoxib is bound to albumin [236]. The high level of protein binding in serum-
containing media would be expected to limit the activity of the compound. Thus, 
in serum-free media, the activity of celecoxib would be expected to be increased, 
thereby lowering the concentration required to effectively inhibit COX-2. 
Concentrations of celecoxib that are approximately 10-fold higher than those 
required for inhibiting COX-2 are known to inhibit other intracellular targets, the 
best characterized being the Akt signaling pathway. In the current studies 
utilizing celecoxib treatments in serum-free media, the lack of protein binding 
may have allowed sufficient inhibition of targets other than COX-2 and the 
observed reduction in expression of differentiation markers. A second potential 
mechanism includes the inhibition of COX-1. Similar to the inhibition of Akt, 
concentrations of celecoxib that are approximately 10-fold higher than those 
required for inhibiting COX-2 result in the inhibition of COX-1. Because individual 
prostanoid synthases are coupled differently to either COX-1 or COX-2, the 
inhibition of COX-1 by celecoxib could result in reduced production of different 
prostanoids than that which results from inhibiting COX-2. It is known that 
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prostacyclin affects cellular differentiation in ways that are opposite of the effects 
of PGE2. Therefore, effects of celecoxib observed in the current studies may 
have also resulted from the inhibition COX-1 resulting in a decrease of 
prostacyclin synthesis [33]. 
Serum-stimulation on the other hand increases COX-2 expression in 
vascular SMCs. An increase in COX-2 protein levels in the cells that had been 
deprived of serum for overnight and then re-stimulated with serum-containing 
growth-promoting media was observed. Even though the increase was sustained 
during the first 2 days after re-stimulation, the COX-2 levels gradually began to 
reduce from the 3rd day onwards (Figure 6.1.2B). It was proposed that celecoxib 
treatment under conditions of increased COX-2 expression would inhibit COX-2 
and induce hASMC differentiation in a dose-dependent manner. Though there 
was a slight trend toward increase in SM22α protein levels in treated cells 
compared with controls after the 2nd day of treatment, this effect was abolished 
by the 3rd day with significant reduction in both α-actin and SM22α protein levels 
in celecoxib-treated cells. Furthermore, there was significant reduction in the 
protein levels of COX-2 at both the 2nd and 3rd day time points in celecoxib-
treated cells compared with controls (Figure 6.2.4).  
The observation of significant reduction in COX-2 levels with celecoxib 
treatment under serum re-stimulated conditions was quite an interesting finding 
(Figure 6.2.4). Celecoxib is a COX-2 inhibitor which acts by inhibiting COX-2 and 
thus preventing it from converting arachidonic acid to the crucial substrate 
(PGH2) which is required for the formation of downstream prostanoids. Even 
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though there are numerous research findings demonstrating the COX-2 inhibitory 
actions of celecoxib, there is a dearth of research showing selective reduction in 
COX-2 expression levels in vascular SMCs by celecoxib treatment. Xu et al 
(1999) reported inhibition of COX-2 transcription with reduction in COX-2 mRNA 
and protein levels by aspirin and sodium salicylate in a cell-cycle specific manner 
[237]. As observed in Figure 6.1.2B, COX-2 protein levels increase when cells 
are serum-stimulated following a 24 hour cell quiescence. By the 3rd day after re-
stimulation, levels of COX-2 begin to decrease. The reason for this reduction in 
COX-2 levels with celecoxib treatment is not known. One potential mechanism 
may result from celecoxib inhibiting the production of a prostanoid that acts to 
increase expression of COX-2. One such prostanoid that has been shown to 
increase expression of COX-2 is PGE2. Our current studies show that PGE2 
synthesis is significantly increased following serum stimulation and this increase 
is significantly inhibited by celecoxib treatment. Therefore, the observed 
reduction in COX-2 expression following celecoxib treatment may have resulted 
from the inhibition of PGE2, thereby limiting the effect of this prostanoid on 
inducing COX-2 expression.  
A limitation of these findings is the fact that even though there is an 
inverse relationship between COX-2 expression and the expression of 
differentiation markers, significant increase in differentiation with celecoxib 
treatment could not be consistently demonstrated under all the cell culture 
conditions studied. In addition, one cannot conclusively attribute the correlation 
observed to causation. It is important to note that COX-2 inhibition just like COX-
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2 deletion, inhibits the production of prostaglandins formed downstream of this 
enzyme. Tang et al (2014) observed that COX-2 deletion in vascular cells in 
animal model of atherosclerosis has been shown to reduce levels of 
prostaglandins while increasing levels of α-actin in these cells [238]. Therefore, 
the increase in differentiation observed with COX-2 inhibition by celecoxib may 
be attributable to the inhibition of specific prostanoids downstream of COX-2 that 
may be important in decreasing differentiation in these cells.  
Moreover, despite the promising findings regarding the effectiveness of COX-
2 inhibition in treatment of AAAs in animal models, as well as the potential for 
celecoxib to promote differentiation or reverse de-differentiation in hASMCs, 
treatment of patients suffering from AAA disease with a COX-2 inhibitor may not 
be a feasible therapeutic option for treating this disease in humans. This is 
because of the increased risk of adverse cardiovascular events associated with 
long-term use of certain COX-2 inhibitors [239, 240]. Therefore, to further 
understand the mechanisms of COX-2 induced SMC phenotypic modulation, key 
mediators of the prostaglandin synthesis pathway downstream of COX-2 which 
have been demonstrated to contribute to AAA development were examined as 
this could potentially provide new targets for treatment of this disease. 
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CHAPTER 7: INHIBITION OF MICROSOMAL PROSTAGLANDIN E 
SYNTHASE AND PROSTAGLANDIN E2 PROMOTES DIFFERENTIATION IN 
HUMAN AORTIC SMOOTH MUSCLE CELLS 
Introduction 
Prostaglandin E2 (PGE2) is the principal prostanoid secreted during 
inflammation and is involved in production of pro-inflammatory cytokines in a 
variety of cells [4, 17, 52, 103-105]. The increased expression of inflammatory 
mediators induced by PGE2 may contribute to alteration of vascular SMC 
contractile function, increased vascular permeability, dilation and pain [4, 52, 85, 
103-105]. PGE2 may be synthesized by conversion of arachidonic acid to the 
substrate PGH2 by the rate-limiting cyclooxygenase enzyme (COX) and 
subsequent action of the Prostaglandin E2 synthase (PGES). PGES exists in 3 
main isoforms: cytosolic (c-PGES), type 1 membrane-associated/microsomal 
(mPGES-1) and type-2 membrane associated (mPGES-2) [106, 107]. However, 
the majority of the PGE2 formed in response to COX-2 induction is dependent on 
mPGES-1 [121, 122].  
In cardiovascular diseases such as abdominal aortic aneurysms (AAAs), 
certain products of the prostanoid synthetic pathway such as COX-2, mPGES-1 
and PGE2 have been implicated in the development of this disease in humans as 
well as in animal models of the disease. Recent studies have shown increased 
expression of COX-2, mPGES-1, and PGE2 synthesis in AAAs [126,147,149, 
150]. Similarly, Wang et al (2008) demonstrated that mPGES-1 deletion in AngII-
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induced AAA mouse models suppressed PGE2 production, and significantly 
attenuated the incidence and severity of AAAs [128]. Also, genetic deletion of 
COX-2 or pharmacological inhibition of this enzyme in an animal model of this 
disease has been shown to reduce the incidence and severity of this disease 
[148, 205].  
Apart from the involvement of mediators of the prostanoid synthetic 
pathway in this disease, reduced differentiation of vascular smooth muscle cells 
within the vessel wall has been observed during the development of AAAs. 
Recent research from our laboratory has demonstrated an inverse association 
between the increase in COX-2 expression within the SMCs of the aneurysmal 
lesions and the reduced expression of differentiation markers. In these studies, 
selective inhibition of the COX-2 enzyme with celecoxib was observed to 
preserve the differentiated phenotype of these cells and significantly attenuate 
AAA progression compared with saline controls [74, 75]. Furthermore, in human 
aneurysmal lesions, reduced expression of markers of differentiation and induced 
expression of de-differentiation markers was observed in the human aortic 
smooth muscle cells [53].  
The mechanisms by which COX-2 promotes reduced differentiation of 
vascular SMCs were investigated by examining prostanoids downstream of the 
COX-2 enzyme. Based on the previous results showing the induction of mPGES-
1 with AngII treatment (Figure 4.3), as well as the promotion of differentiation in 
cells treated with celecoxib (Figure 5.1), the hypothesis that COX-2 may 
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contribute to reduced differentiation in vascular SMCs by the action of mPGES-1-
derived PGE2 was proposed. 
To understand the mechanisms by which the inducible cyclooxygenase 
enzyme (COX-2) contributes to reduced differentiation observed during 
development of abdominal aortic aneurysms (AAA), human aortic smooth muscle 
cells (hASMCs) as our in vitro cell culture model were utilized to study the effects 
of various treatments on modulation of the cell phenotype. hASMCs were 
cultured under different conditions and treated with PGE2 exogenously over time. 
Furthermore, the contribution of endogenous mPGES-1-derived PGE2 on the cell 
phenotype by inhibiting mPGES-1 both pharmacologically (15-dPGJ2) and 
genetically (mPGES-1 siRNA) were examined. The concentration PGE2 
synthesized under various treatment conditions was measured via enzyme 
immune assay while mRNA expression and protein levels of a wide variety of 
markers of the differentiated as well as de-differentiated phenotype were 
examined by real-time PCR and western blotting, respectively.  
 
Results 
7.1 Effect of Prostaglandin E2 on hASMC phenotype 
7.1.1 Prostaglandin E2 treatment under differentiation-promoting conditions 
reduces differentiation in hASMC 
To study the role of PGE2 on the hASMC phenotype, cells were cultured 
under differentiation-promoting conditions and treated with PGE2 under 
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conditions promoting either differentiation. Cells were plated directly into cell 
culture plates in differentiation promoting media for 2 days. At the 2 day time- 
point, cells were treated with either 0.2 µM or 1 µM PGE2 under conditions 
promoting differentiation. Vehicle-treated controls were treated with 0.1% ethanol 
under the same conditions. Protein levels of α-actin were measured via 
immunocytochemistry and normalized to cellular DNA detection as determined 
by SYBR green detection at each time point.  
Treatment of differentiated cells with PGE2 under differentiation-promoting 
conditions, resulted in a dose-dependent trend toward reduction in α-actin levels 
which was significant with 1 µM treatment at the 1 day time point (Figure 7.1.1A) 
but not after 2 days (Figure 7.1.1B).  
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Figure 7.1.1 Prostaglandin E2 treatment under differentiation-promoting 
conditions reduces α-actin levels in differentiated hASMCs  
Immunocytochemistry with fluorescent imaging quantitation showing α–actin 
expression in differentiated cells treated with PGE2 under differentiation- 
promoting conditions for (A) 1 day or (B) 2 days. Data represents mean + SEM 
(n=3), * = p < 0.05; one-way ANOVA and post hoc analysis with Dunnett’s 
Multiple Comparison test. 
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7.1.2 Prostaglandin E2 treatment under de-differentiation-promoting 
conditions reduces α-actin levels in differentiated hASMCs  
Previously, increased synthesis of mPGES-1 (the major enzyme that 
produces PGE2) was observed in differentiated hASMCs treated with AngII under 
de-differentiation-promoting conditions (Figure 4.3). Therefore, to study the role 
of PGE2 on the phenotype of differentiated cells treated with PGE2 under 
conditions promoting growth, cells were cultured under differentiating-promoting 
conditions for 2 days and subsequently treated with either 0.2 µM or 1 µM PGE2 
in de-differentiation-promoting media for either 1 or 2 days. Vehicle-treated 
controls were treated with 0.1% ethanol under the same conditions. At each time 
point, cells were lysed, harvested, and analyzed for α-actin protein levels via 
western blotting.  
The treatment of hASMCs with PGE2 under growth-promoting conditions 
for 1 day significantly reduced α-actin levels compared with controls (Figure 
7.1.2A). Although there was a trend toward a reduction in α-actin levels with the 1 
µM PGE2 concentration after 2 days of treatment, this effect was not statistically 
significant (Figure 7.1.2B).  
Figure 7.1.2 Prostaglandin E2 treatment under de-differentiation-promoting 
conditions reduces α-actin levels in differentiated hASMCs  
Densitometry and representative western blot showing protein levels of α-actin in 
hASMCs cultured under differentiation-promoting conditions and treated with 
PGE2 for either (A) 1 day, or (B) 2 days under conditions promoting de-
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7.2 Prostaglandin E2 inhibits the induction of differentiation in hASMCs 
To further examine the effects of PGE2 on phenotypic modulation, the role 
of PGE2 on the induction of differentiation in these cells was explored. As an 
alternative method of inducing differentiation and examining the effects of various 
treatments under conditions without the potential for interaction with serum-
containing components, cells were cultured in de-differentiation-promoting media 
for 2 days and then deprived of serum over time. Previous findings with serum-
deprivation indicated that after 2 days of serum deprivation, the cells began to 
differentiate as indicated by a 5-fold increase in SM α-actin, as compared to non-
serum-deprived controls (Figure 4.2). After 3 days in serum-free medium, the 
cells demonstrated significantly increased levels of both α-actin and SM22α. 
7.2.1 Prostaglandin E2 treatment initiated after 2 days of serum-deprivation 
reduces α-actin protein levels in hASMCs 
Differentiation was induced hASMCs by the serum-deprivation method 
and then the cells were treated with either 0.2 µM or 1 µM PGE2 in serum-free 
media at the 2 day time point. Cells were treated with PGE2 for between 1 to 3 
days and cell lysates were collected at each time point and analyzed by 
measuring protein levels of α-actin via western blotting.  
In cells deprived of serum for 2 days, significant reduction α-actin protein 
levels after treatment with PGE2 at the 1, 2 and 3 day time points was observed 
(Figure 7.2.1). Surprisingly, the reduction in α-actin observed with 0.2 µM PGE2 
was greater than that observed at the higher concentration of 1 µM. In addition, 
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7.2.2 Prostaglandin E2 treatment initiated after 3 days of serum-deprivation, 
reduces protein levels of SMC markers of differentiation 
In previous experiments, significant induction of markers of differentiation 
in serum-deprived hASMCs from the 3 day time point onwards had been 
observed. Thus, in order to study the effect of PGE2 treatment on differentiation, 
the treatment was commenced at the 3-day time point of serum-deprivation. 
Cells were treated with PGE2 for either 1 or 2 days and cell lysates were 
collected at each time point and analyzed by measuring protein levels of α-actin 
and SM22α via western blotting.  
Similar to PGE2 treatment after 2 days of serum-deprivation, treatment 
after 3 days resulted in significant reduction of both α-actin and SM22α protein 
levels, as compared with vehicle-treated controls. However, at both time points, 
there was a greater reduction in SM22α levels than with α-actin levels, indicated 
by the increased significant difference between treated and control cells in the 
SM22α group, as compared to the α-actin group. 
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extent of reduction was observed with mRNA expression of Myosin Heavy Chain 
II (Myh11) at both time points. Even though significant reduction in α-actin 
expression was observed with 1 day treatment, the expression ceased to be 
significant at the 2 day time point, as there was observed an upward trend in α-
actin expression in PGE2 treated cells.  
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Figure 7.2.3 Prostaglandin E2 treatment initiated after 3 days of serum-
deprivation reduces mRNA levels of SMC markers of differentiation 
mRNA expression of (A) α-actin, (B) Smooth muscle 22α (C) Myosin heavy chain 
II (D) Smoothelin in hASMCs following incubation in serum-free media for 3 days 
and then treated with PGE2 in serum-free media for 1 or 2 days. Data represents 
the mean + SEM (n≥3), * = p < 0.05, *** = p < 0.001; one-way ANOVA (Dunnett’s 
Multiple comparison test). 
1 day 
 
 
 
 
130 
 
Figure 7.2.3 (continued) 
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Figure 7.2.3 (continued) 
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Figure 7.2.3 (continued) 
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Figure 7.2.3 (continued) 
 
7.2.4 Prostaglandin E2 treatment initiated after 3 days of serum-deprivation 
induces mRNA levels of SMC markers of de-differentiation 
Since it was observed that PGE2 treatment reduces differentiation marker 
expression in hASMCs, the effect of PGE2 treatment on the expression of 
markers of de-differentiation was also examined in these cells. Cells were 
deprived of serum for 3 days and treated with either 0.2 µM or 1 µM PGE2 over a 
2-day time period. mRNA was isolated from cell lysates at each time point, and 
examined for the expression of the de-differentiation markers HAS2 and MMP2, 
by real-time PCR. 
 Neither HAS2 nor MMP2 mRNA levels were significantly different between 
cells treated with vehicle or PGE2 for 1 day. However, at the 2 day time point, a 
dose-dependent significant increase in mRNA expression for both MMP2 and 
HAS was observed following PGE2 treatment. 
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Figure 7.2.4 Prostaglandin E2 treatment initiated after 3 days of serum-
deprivation induces mRNA levels of SMC markers of de-differentiation 
mRNA expression of (A) HAS2, and (B) MMP2 in hASMCs serum starved for 3 
days and then treated with PGE2 for 1 or 2 days. Data represents the mean + 
SEM (n≥3), * = p < 0.05; one-way ANOVA (Dunnett’s Multiple comparison test) 
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Figure 7.2.4 (continued) 
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7.3 Inhibition of mPGES-1 promotes hASMC differentiation 
7.3.1 Serum-stimulation increases endogenous concentrations of PGE2  
 In order to further examine the role of PGE2 in hASMC phenotypic 
modulation, endogenous production of PGE2 under different cell culture 
conditions was assessed. The cells were cultured under conditions of serum-
deprivation or serum-stimulation and the levels of PGE2 produced by the cells 
were determined.  
hASMCs were cultured under growth-promoting conditions for 2 days, 
then the media was changed to serum-free media overnight, and then the cells 
were re-stimulated with growth promoting media. At the point of re-stimulation, 
the control cells were treated with fresh serum-free media, thus leaving these 
cells unstimulated. After 1 day, cell culture media was collected and then 
analyzed for PGE2 concentrations via enzyme immunoassay. 
Significant reduction in PGE2 concentrations in media obtained from cells 
maintained in serum-free media, compared with cells stimulated with serum-
containing media was observed (Figure 7.3.1). There was about a 20-fold 
increase in PGE2 concentrations produced in cells that were in serum-containing 
media compared with cells in serum-free media. Therefore, the method of serum-
stimulation to increase PGE2 concentrations endogenously was subsequently 
used. 
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Figure 7.3.1 Serum-stimulation increases endogenous concentrations of 
PGE2  
Enzyme immunoassay analysis of PGE2 concentrations in culture media obtained 
from cells cultured for 1 day under re-stimulated or unstimulated conditions. Data 
represents the mean + SEM (n≥3) **** = p < 0.0001; unpaired Student’s t-test. 
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7.3.2 Inhibition of COX-2 or mPGES-1 reduces PGE2 concentrations in 
hASMCs  
Since it was previously demonstrated that that exogenous addition of 
PGE2 to differentiated or serum-deprived cells reduced hASMC differentiation 
(see sections 7.1 and 7.2), the effect of endogenously produced PGE2 on the 
hASMC phenotype was examined. PGE2 production was stimulated 
endogenously by serum-stimulation as shown above (7.3.1), and then treated the 
cells with appropriate inhibitors under these conditions.  
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Previous results (see Figure 6.1.2A) as well as current literature [220-223] 
had shown that COX-2 is activated during re-stimulation with serum, therefore, 
the effect of COX-2 inhibition on PGE2 production was initially examined. The 
hASMCs were cultured under de-differentiation-promoting conditions for 2 days, 
the media was changed to serum-free media overnight, and then the cells were 
re-stimulated with de-differentiation-promoting media containing varying 
concentrations of celecoxib (0.01 µM, 0.1 µM, and 5 µM) or vehicle. After 1 day, 
the cell culture media was collected and then analyzed for PGE2 concentrations 
via enzyme immunoassay.  
There was a dose-response effect observed with celecoxib treatment 
under conditions of re-stimulation. Compared to vehicle-treated controls, the 
highest concentration of celecoxib used (5 µM) provided the greatest reduction in 
PGE2 observed in these cells (about 800-fold reduction), followed by 0.1 µM 
(about 400-fold reduction), and then 0.01 µM (about 50-fold reduction) (Figure 
7.3.2A). 
Current research indicates that mPGES-1 is generally found to be co-
expressed with COX-2 in vivo and in vitro [17, 106, 108, 111, 113-119]. 
Therefore, the effect of pharmacological inhibition of mPGES-1 on PGE2 
concentrations in hASMCs under conditions of re-stimulation was examined. 
hASMCs were cultured under de-differentaition-promoting conditions for two 
days and then made quiescent by changing to serum-deprived medium for 1 day. 
After 1 day of serum-deprivation, cells were treated for 1 day with de-
differentiation-promoting media containing either celecoxib, or 15d-PGJ2 
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(mPGES-1 inhibitor). As a positive control, cells were cultured under the same 
conditions but replaced with serum-deprived media (unstimulated) containing 
0.1% ethyl acetate, while negative control cells were re-stimulated with growth-
promoting media (re-stimulated) containing vehicle (0.1% ethyl acetate). Cell 
media was collected for measurement of PGE2 concentrations via enzyme 
immunoassay analysis (EIA).  
Significant increase in PGE2 concentrations in re-stimulated cells was 
observed compared with unstimulated cells (Figure 7.3.2B). Treatment of cells 
with celecoxib (COX-2 inhibitor) significantly reduced PGE2 levels beyond the 
levels observed with unstimulated cells. Compared with the re-stimulated 
controls, 15d-PGJ2 also reduced significantly PGE2 concentrations in treated 
cells, though not to the extent observed by celecoxib treatment or by serum-
deprivation. Overall, compared with re-stimulated controls, celecoxib treatment 
had the greatest effect on reducing PGE2 levels with about an 800-fold reduction 
observed. Treatment with either 0.1 µM or 1 µM 15d-PGJ2 yielded about a 10-
fold reduction in PGE2 concentrations compared with re-stimulated controls. 
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Figure 7.3.2 Inhibition of COX-2 or mPGES-1 reduces PGE2 concentrations 
in hASMCs  
Enzyme immunoassay analysis (EIA) of PGE2 concentrations in hASMCs treated 
with (A) varying concentrations of celecoxib for 1 day under conditions of re-
stimulation. (B) celecoxib, and varying concentrations of 15d-PGJ2 under 
conditions of re-stimulation. Data represents mean + SEM (n = 4), ****= P < 
0.0001 one-way ANOVA (Dunnetts multiple comparison test).  
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Figure 7.3.2 (continued) 
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7.3.3 mPGES-1 inhibition by 15d-PGJ2 increases α-actin protein levels in 
hASMCs cultured under serum-deprivation, serum-stimulation, and de-
differentiation-promoting conditions  
In order to examine the effect of pharmacological inhibition of mPGES-1 
and PGE2 synthesis, cultured cells were treated with an mPGES-1 inhibitor (15d-
PGJ2) under conditions of serum-deprivation and serum-stimulation. Cells were 
serum-deprived for 1 day and then treated with varying concentrations of 15d-
PGJ2 in either serum-deprived media or de-differentiation-promoting media 
(serum stimulation). Control cells were treated with vehicle (0.1% ethyl acetate). 
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After 1 day of treatment, cells were fixed and analyzed for α-actin expression via 
immunocytochemistry. 
Results showed that α-actin levels increased in cells treated with 15d-
PGJ2 under both conditions. The increase observed with treatment under serum-
deprivation conditions was significant compared with vehicle-treated controls. 
However, though there was a trend towards increase in α-actin levels with 
treatment under conditions of re-stimulation, this effect was not significant. Since 
treatment with either 0.1 or 1.0 µM of 15d-PGJ2 did not result in significant 
induction of α-actin, differentiated cells were treated with a higher concentration 
of 15d-PGJ2 (10 µM), under de-differentiation-promoting conditions for 1 day, and 
α-actin expression was examined via immunocytochemistry.   
Significant induction in α-actin protein levels in cells treated with 10 µM of 
15d-PGJ2 under de-differentiation-promoting conditions was observed compared 
with vehicle-treated controls (Figure 7.3.3). 
 
Figure 7.3.3 mPGES-1 inhibition by 15d-PGJ2 increases α-actin protein 
levels in hASMCs cultured under serum-deprivation, serum-stimulation, 
and de-differentiation-promoting conditions 
Immunocytochemistry with fluorescent imaging quantitation showing α–actin 
expression in hASMCs treated with 15d-PGJ2 for 1 day under (A) serum-free 
conditions and (B) serum-stimulated conditions (C) de-differentiation-promoting 
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conditions. Data represents mean ± SEM (n = 4), ***= P < 0.001; unpaired 
Student’s t-test for (A) and (C); one-way ANOVA for (B). 
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Figure 7.3.3 (continued) 
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7.3.3.1 Rosiglitazone (PPARɣ agonist) does not increase α-actin protein 
levels in hASMCs  
In order to ascertain if the increase in α-actin observed with 15d-PGJ2 
treatment was due to mPGES-1 inhibition and not by the activation of PPARɣ, 
rosiglitazone a PPARɣ agonist, was used to treat the cells and the effect on the 
hASMC phenotype was examined. Cultured hASMCs were treated with varying 
concentrations of rosiglitazone under conditions promoting differentiation (serum-
deprived) or de-differentiation (serum-stimulated) for 1 day and then protein 
levels of α-actin were subsequently measured by western blotting. Vehicle-
treated controls were treated with media containing 0.1% DMSO. After 1 day of 
incubation, cells treated with rosiglitazone under serum-deprived conditions were 
fixed and analyzed for α-actin expression via immunocytochemistry whereas, 
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rosiglitazone-treated cells under conditions promoting de-differentiation were 
lysed and harvested for analyses via western blotting. 
Results showed that α-actin levels did not increase in cells treated with 
Rosiglitazone under either condition. Under conditions of serum-deprivation, 
there was significant reduction in α-actin levels upon treatment with both 1 and 
10µM Rosiglitazone (Figure 7.3.4A). In addition, under serum-stimulated 
conditions, rosiglitazone treatment did not induce any increase in α-actin protein 
levels in treated cells (Figure 7.3.4B).  
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Figure 7.3.3.1 Rosiglitazone (PPARɣ agonist) does not increase α-actin 
protein levels in hASMCs  
(A) Immunocytochemistry with fluorescent imaging quantitation showing α–actin 
expression in hASMCs treated with Rosiglitazone for 1 day under serum-
deprived conditions and (B) Representative western blot with densitometry 
quantitation showing α–actin expression in hASMC treated with Rosiglitazone for 
1 day under serum-stimulated conditions. Data represents mean ± SEM (n = 4), 
***= P < 0.001; one-way ANOVA with Dunnetts post hoc test for (A) and unpaired 
Student’s t-test for (B). 
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media was replaced with serum-free media for 2 days. After each day of serum 
deprivation, cell culture media was collected for PGE2 analysis by enzyme 
immune assay while cells were lysed and analyzed for either mRNA or protein 
expression.  
7.3.4.1 siRNA mediated mPGES-1 knockdown induces mRNA expression of 
SMC markers of differentiation after 1 day of serum-deprivation 
mPGES-1 siRNA-transfected cells were cultured for 2 days under de-
differentiation-promoting conditions and then serum deprived for 1 day. Cells 
were lysed, harvested, and mRNA was isolated after 1 day in serum-free media. 
mRNA expression levels of mPGES-1, and a variety of markers of differentiation 
(α-actin, SM22α, and smoothelin) was subsequently examined.  
Significant reduction in mPGES-1 mRNA expression was observed after 1 
day of serum-deprivation and this was associated with a significant increase in 
the mRNA expression of α-actin and smoothelin (Figure 7.3.4.1). Although there 
was a trend toward an increase in SM22α expression in mPGES-1 siRNA 
transfected cells, this effect was not significantly different compared with the 
control cells.  
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Figure 7.3.4.1 siRNA mediated mPGES-1 knockdown induces mRNA 
expression of SMC markers of differentiation after 1 day of serum-
deprivation 
mRNA expression of (A) mPGES-1, (B) α-actin, (C) SM22α (D) Smoothelin in 
hASMCs transfected with mPGES-1 siRNA for 2 days in growth promoting media 
and then switched to serum-free media for 1 day. Data represents the mean + 
SEM (n≥3), * = p < 0.05, **** = p < 0.0001; unpaired Student’s t-test. 
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Figure 7.3.4.1 (continued) 
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Figure 7.3.4.1 (continued) 
 
 
7.3.4.2 siRNA mediated mPGES-1 knockdown induces mRNA expression of 
SMC markers of differentiation after 2 days of serum-deprivation 
mPGES-1 siRNA-transfected cells were cultured for 2 days under de-
differentiation-promoting conditions and then serum deprived for 2 days. Cells 
were lysed, harvested, and mRNA was isolated after 2 days in serum-free media. 
mRNA expression levels of mPGES-1, and a variety of markers of differentiation 
(α-actin, SM22α, and smoothelin) was subsequently examined.  
There was significant reduction in mPGES-1 mRNA expression after 2 
days of serum-deprivation and this was associated with significant increase in the 
mRNA expression of α-actin and smoothelin (Figure 7.3.4.2). Similar to the 1 day 
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experiment, the increase in SM22α expression in mPGES-1 siRNA transfected 
cells was not statistically significant.  
Figure 7.3.4.2 siRNA mediated mPGES-1 knockdown induces mRNA 
expression of SMC markers of differentiation after 2 days serum-
deprivation 
mRNA expression of (A) mPGES-1 (B) α-actin, (C) SM22α, and (D) Smoothelin 
in hASMCs transfected with mPGES-1 siRNA for 2 days in de-differentiation-
promoting media and then switched to serum-free media for 2 days. Data 
represents the mean + SEM (n≥3), (n = 2 for mPGES-1), *= p< 0.05, *** = p < 
0.001; unpaired Student’s t-test. 
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Figure 7.3.4.2 (continued) 
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Figure 7.3.4.2 (continued) 
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7.3.4.3 siRNA mediated mPGES-1 knock-down increases protein levels of 
SMC markers of differentiation after serum-deprivation for 1 day 
Protein levels of mPGES-1 and markers of differentiation in cells 
transfected with mPGES-1 siRNA and compared these with vehicle-transfected 
cells were examined. hASMCs were transfected with mPGES-1 siRNA and 
cultured for 2 days in de-differentiation-promoting media. After 2 days of 
incubation, the cell media was changed to serum-deprived media and then cells 
were lysed, harvested and analyzed by western blotting after 1 day of incubation 
in serum-free media. 
 The treatment of hASMCs with mPGES-1 siRNA resulted in a significant 
reduction in mPGES-1 protein levels and this was associated with a significant 
increase in protein levels of the differentiation markers, α-actin and SM22α 
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7.3.4.4 siRNA-mediated mPGES-1 knock-down increases protein levels of 
SMC markers of differentiation after serum-deprivation for 2 days 
Protein levels of mPGES-1 and markers of differentiation in cells 
transfected with mPGES-1 siRNA were examined and compared these with 
vehicle-transfected cells. hASMCs were transfected with mPGES-1 siRNA and 
cultured for 2 days in growth promoting media. After 2 days of incubation, the cell 
media was changed to serum-deprived media and then cells were lysed, 
harvested and analyzed by western blotting after 2 days of incubation in serum-
free media. 
 A trend toward a reduction in mPGES-1 levels was observed though this 
was not significant. However, there was a significant increase in protein levels of 
both α-actin and SM22α in mPGES-1 siRNA transfected cells (Figure 7.3.4.4). 
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7.3.4.5 siRNA-mediated mPGES-1 knockdown reduces mRNA expression of 
SMC markers of de-differentiation 
With the finding that the knockdown of mPGES-1 increased the 
expression of differentiation markers, the effect of mPGES-1 knockdown on the 
expression of markers of the de-differentiated phenotype in hASMCs was 
examined. HAS2 and MMP-2 are both markers of the synthetic phenotype which 
are associated with decreased differentiation of vascular SMCs in certain 
cardiovascular diseases [53, 74]. Therefore, mRNA expression of HAS2 and 
MMP2 were examined in hASMCs transfected with mPGES-1 siRNA and then 
compared with vehicle-transfected cells. 
hASMCs were transfected with mPGES-1 siRNA and cultured for 2 days 
in growth-promoting media. After 2 days of incubation, the cell media was 
changed to serum-deprived media and incubated for 2 days. Cells were lysed, 
harvested, and mRNA was isolated for real-time PCR analysis at each after 
either 1 or 2 days in serum-deprived media. Significant reduction in both HAS2 
and MMP2 mRNA expression levels in the mPGES-1 siRNA-transfected cells 
was observed, as compared with vehicle-treated controls (Figure 7.3.4.6). 
Figure 7.3.4.5 siRNA-mediated mPGES-1 knockdown reduces mRNA 
expression of SMC markers of de-differentiation.  
mRNA expression of (A) HAS2, and (B) MMP2 in hASMCs transfected with 
mPGES-1 siRNA for 1 or 2 days in growth promoting media and then switched to 
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serum-free media. Data represents the mean + SEM (n≥3), **= p< 0.01, ***= p< 
0.001; unpaired Student’s t-test. 
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Figure 7.3.4.5 (continued) 
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7.4 PGE2 regulates COX-2 expression in hASMCs 
7.4.1 PGE2 treatment increases COX-2 expression under serum-deprivation 
conditions  
The presence of a feedback loop between PGE2 and COX-2 in which 
increased synthesis of PGE2 either promotes induction of COX-2 expression 
(positive feedback) [124, 125, 241] or reduces COX-2 expression (negative 
feedback) [242-244] has been demonstrated in a variety of cell types. Due to 
these different reports regarding the regulation of COX-2 expression by PGE2, 
the expression levels of COX-2 in these hASMCs both after treatment with PGE2 
exogenously, and after mPGES-1 siRNA-mediated knock down were examined. 
Cells were cultured under de-differentiation-promoting conditions for 2 days and 
then deprived of serum for 3 days. At this point, 1 µL of either 0.2 mM or 1.0 mM 
of PGE2 was added to the media for 1 or 2 days after which mRNA was isolated 
from the cells and then analyzed for COX-2 expression via real-time PCR.  
At each time point, there was significant increase in COX-2 mRNA 
expression with PGE2 treatment compared with untreated controls (Figure 7.4.1). 
At the 2-day time point, there was about a 5-fold increase in COX-2 mRNA 
expression levels in cells treated with 1 µM PGE2 compared with the vehicle-
treated control. 
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Figure 7.4.1 PGE2 treatment increases COX-2 expression under serum-
deprivation conditions  
mRNA expression of COX-2 in hASMCs serum starved for 3 days and then 
treated with PGE2 for (A) 1 day or (B) 2 days. Data represents the mean + SEM 
(n=3), **= p< 0.01; one-way ANOVA (Dunnetts Multiple comparison test)
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7.4.2 mPGES-1 mediated siRNA knock-down reduces COX-2 expression 
under serum-deprivation conditions over time 
Since exogenous PGE2 treatment induced COX-2 mRNA expression in 
treated cells (7.4.1), the effect of endogenous loss of PGE2 on the expression of 
COX-2 in these hASMCs was examined. Cells were cultured directly in de-
differentiation-promoting media containing mPGES-1 siRNA for 2 days and then 
the culture media was changed to serum-free media for 1 to 2 days. At each time 
point, cells were harvested and mRNA was isolated for analysis by real-time 
PCR. In cells treated with mPGES-1 siRNA, significant reduction in COX-2 
mRNA expression compared with vehicle-transfected controls was observed at 
each time point (Figure 7.4.2). 
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Figure 7.4.2 mPGES-1 mediated siRNA knock-down reduces COX-2 
expression under serum-deprivation conditions over time 
mRNA expression of COX-2 in hASMCs transfected with mPGES-1 siRNA for 2 
days in growth promoting media and then switched to serum-free media for (A) 1 
day or (2) 2 days. Data represents the mean + SEM (n≥3), *= p< 0.05, *** = p < 
0.001; unpaired Student’s t-test. 
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7.5 PGE2 treatment reduces mPGES-1 expression in hASMCs 
mPGES-1 has been reported to be co-expressed and functionally coupled 
with COX-2 in response to a range of extracellular and intracellular stimuli [17, 
106, 108, 111, 113, 117-120]. However, other investigators have demonstrated 
that mPGES-1 and COX-2 are neither co-expressed nor functionally coupled [79, 
245, 246]. Therefore, upon observing the increase in COX-2 mRNA with PGE2 
treatment and the decrease in COX-2 expression in cells transfected with 
mPGES-1 siRNA, the expression of mPGES-1 in PGE2-treated cells was 
examined in order to determine if the expression patterns between both enzymes 
would be similar. Cultured hASMCs were serum-deprived for 3 days and then 
treated with PGE2 for either 1 or 2 days. Cells were harvested and mRNA was 
isolated and analyzed for mPGES-1 expression via real-time PCR. PGE2 treated 
cells did not increase mPGES-1 levels as observed with COX-2 treatment in 
Figure 7.4.1. On the contrary, significant reduction in mPGES-1 mRNA levels 
were observed with PGE2 treatment at both time points (Figure 7.5.1).  
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Figure 7.5 PGE2 treatment reduces mPGES-1 mRNA expression in hASMCs 
mRNA expression of mPGES-1 in hASMCs serum deprived for 3 days and then 
treated with PGE2 for (A) 1 day and (B) 2 days. Data represents the mean + SEM 
(n≥3), **= p< 0.01, ***= p< 0.001; one-way ANOVA (Dunnetts Multiple 
comparison test). 
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7.6 Small interfering RNA (siRNA) mediated mPGES-1 knockdown reduces 
PGE2 production by hASMCs 
The effect of mPGES-1 siRNA-mediated knock-down on the production 
and release of PGE2 into the cell culture media at each time point was examined. 
hASMCs were transfected with mPGES-1 siRNA according to the manufacturer’s 
protocol via the reverse transfection method and plated the cells in de-
differentiation-promoting media for 2 days. Control wells were treated with the 
transfection agent in the absence of the siRNA. After 2 days of incubation, the 
media was replaced with serum-free media and then collected after either 1 or 2 
days. Subsequently, the media was assessed for PGE2 concentration via enzyme 
immunoassay analysis.  
Following mPGES-1 siRNA transfection, knockdown of mPGES-1 mRNA 
resulted in reduced PGE2 concentrations after both days. However, this effect 
was significant only at the 2-day time point (Figure 7.6). 
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Figure 7.6 siRNA mediated mPGES-1 knock down reduces PGE2 
concentrations in hASMCs 
Enzyme immunoassay analysis of PGE2 concentrations in cells transfected with 
mPGES-1 siRNA for 2 days and then deprived of serum for (A) 1 day, or (B) 2 
days. Data represents mean + SEM (n = 4), ***= p < 0.001; unpaired Student’s t-
test. 
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7.7 Effect of EP4 receptor activation by CAY10580 on hASMC differentiation 
PGE2 exerts its actions via a family of G-protein coupled receptors: EP1, EP2, 
EP3 and EP4 having unique tissue expression profiles and whose effects are 
mediated through different downstream signaling pathways [79, 127-129]. EP4 
receptor protein has been shown to be present in AAA lesions of both mice and 
human samples, and inhibition of this receptor in mice results in reduction of the 
incidence and severity of AAAs [133, 134]. On the contrary, the deletion of the 
EP4 receptor on bone-marrow-derived cells has been shown to enhance the 
formation of AAAs in AngII-induced mouse models of the disease [247].  
Based on the findings implicating EP4 receptor activation in the development 
of AAAs, the hypothesis stating that activation of the EP4 receptor will reduce 
differentiation of hASMCs was proposed. To test this hypothesis, cells were 
treated with CAY10580, which is a potent EP4 receptor agonist. The experiments 
were performed under different cell culture conditions and the effect on the 
expression of differentiation markers was measured.  
 
7.7.1 EP4 receptor activation by CAY10580 does not promote de-
differentiation in hASMCs cultured under serum-deprivation conditions.  
The effect of EP4 receptor activation on the induction of differentiation in 
serum-deprived cells was examined. Cultured cells were serum deprived over a 
2 day or 3 day time period and then treated with 0.1 µM CAY10580 for 1 to 2 
days. At each time point, cells were lysed, harvested and analyzed for α-actin, 
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Figure 7.7.2 EP4 receptor activation by CAY10580 reduces α-actin levels in 
hASMCs cultured under conditions promoting differentiation 
mRNA expression of α-actin in hASMCs treated with CAY10580 under conditions 
promoting differentiation for 1 day. Data represents the mean + SEM (n=4), **= 
p< 0.01 unpaired Student’s t-test. 
 
 
 
Discussion 
Among the COX-2-derived prostanoids, PGE2 is a major component of the 
pro-inflammatory cascade which has been implicated in the pathology of 
numerous diseases including cancer, arthritis, atherosclerosis, and aneurysms 
[17, 123, 141, 149, 233, 248-250]. Furthermore, mPGES-1, which is the major 
PGE2-synthesizing enzyme, has been shown to be co-expressed with COX-2 in 
**
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vitro and in vivo [17, 122, 231, 233]. Since an increase in COX-2 has been 
implicated in the reduced expression of differentiation markers during 
development of AAAs, and an increase in mPGES-1 and PGE2 has been 
detected in aneurysmal lesions compared to normal aorta, the mechanism by 
which COX-2 may be inducing de-differentiation was proposed to be via the 
action of mPGES-1-derived PGE2 [74, 126, 128, 147-150]. Using an in vitro 
model of cultured hASMCs, the role of PGE2 in phenotypic modulation was 
investigated by measuring expression of markers of differentiation and de-
differentiation after exogenous PGE2 treatment and the inhibition of mPGES-1-
derived PGE2. It was proposed that COX-2 may be contributing to reduced 
differentiation of the vascular SMCs by increasing production of PGE2.  
Cells were cultured under conditions promoting differentiation using 
differentiation-promoting media and treated with PGE2 under either de-
differentiation-promoting or differentiation-promoting conditions. With 
differentiated hASMCs treated with PGE2 under conditions promoting 
differentiation, both a concentration-dependent decrease in α-actin protein levels 
and a statistically significant reduction with a 1 µM PGE2 treatment at the 1 day 
time point were observed (Figure 7.1.1). Although there was a trend toward 
reduction of α-actin protein levels with 1 µM PGE2 at the 2-day time point, the 
effect was not statistically significant. This may be due to PGE2 degradation in 
the media over time. The treatment of differentiated cells with PGE2 under 
conditions promoting de-differentiation for 1 day also significantly decreased α-
actin protein levels and the effect was more significant than that observed with 
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treatment under differentiation-promoting conditions (Figure 7.1.2). Treatment 
with PGE2 for 2 days under conditions promoting de-differentiation however, did 
not yield significant reduction in α-actin possibly due to degradation of the PGE2 
in the media over time. The reduction induced by PGE2 under these conditions 
exceeded that observed with differentiation-promoting media possibly due to the 
fact that the increased serum and growth factors present in this de-differentiation-
promoting media, may reduce differentiation, and thus potentiate the α-actin–
reducing effects of PGE2 under these conditions (Figure 7.1.2). Media containing 
increased serum and growth factors have been shown to contribute to reduced 
expression of differentiation markers in vascular SMCs (45, 46, 54, 56-58). 
Therefore, treating the hASMCs with PGE2 under these conditions may further 
potentiate this reduction in differentiation demonstrated by the greater decrease 
in α-actin levels in these cells at the 1 day time point. 
Since PGE2 was observed to reduce differentiation in hASMCs, the effect 
of PGE2 treatment on the induction of differentiation by serum-deprivation was 
examined. Vascular SMCs when deprived of serum over time have been shown 
to induce differentiation by upregulating the expression of markers of vascular 
SMC differentiation [23, 172-174]. This effect was also observed in the current 
studies with hASMCs as shown by the increase in α-actin and SM22α (Figure 
4.2). hASMCs which were induced to differentiate under conditions of serum-
deprivation with PGE2 were treated for either 1 or 2 days in order to determine if 
PGE2 would prevent induction of differentiation under these conditions. 
Treatment of serum-deprived cells with PGE2 over time beginning either at the 2 
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or 3 day time point resulted in significant reduction in both mRNA and protein 
levels of differentiation markers. Even though serum-deprivation over time was 
expected to induce expression of differentiation markers, PGE2 treatment 
inhibited this induction and also reversed differentiation in these cells (See 
section 7.2). Although the observed reduction in protein levels of α-actin and 
SM22α was significant, the reduction observed with the 0.2 µM treatment of 
PGE2 was greater than that observed with the 1 µM treatment. This could be 
attributed to off-target effects occurring in cells treated with higher concentration 
of PGE2 under serum-starved conditions.  
The effect of PGE2 treatment on the expression of markers of de-
differentiation under conditions of serum-deprivation was also examined. The 
results showed that PGE2 treatment increases expression of markers of de-
differentiation, although the time required for producing the effect was different 
than for the differentiation markers. Although treatment with PGE2 for 1 day did 
not increase expression of these markers, treatment for 2 days did result in the 
significant induction of mRNA expression of both HAS2 and MMP2 in these cells.  
PGE2 has been observed to alter the differentiation state of a variety of 
cell types in vitro and in vivo. For example, PGE2 has been shown to induce the 
differentiation of myeloid-derived suppressor cells (MDSC) from bone marrow 
stem cells thereby promoting proliferation and malignancy of tumor cells in the 
pathogenesis of cancer [251]. In addition, PGE2 has been shown to inhibit 
expression of differentiation markers in human lung fibroblast cells [252, 253]. In 
vascular SMCs, analogues of prostacyclin or PGE2 increase expression of HAS2 
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mRNA and the synthesis of hyaluronic acid [34]. In SMCs induced to de-
differentiate following treatment with interleukin-1beta, PGE2 treatment was 
shown to enhance actin filament disorganization, although no changes in the 
expression of differentiation markers was reported[104]. These findings 
demonstrate that in hASMCs, exogenous PGE2 treatment under a variety of 
culture conditions promotes a reduction in the expression of multiple markers of 
differentiation. Furthermore, PGE2 treatment induces the expression of markers 
of the synthetic phenotype thus promoting the de-differentiation of these cells.  
The isoprostane 15-deoxy-∆(12,14)-prostaglandin J(2) (15d-PGJ2), is a 
commercially available pharmacological agent which has been shown to be a 
potent inhibitor of mPGES-1 in vitro [254]. Recent reports have demonstrated 
that 15-dPGJ2 inhibits human mPGES-1 both covalently (by modification of 
residue C59) and non-covalently (by binding to the PGH2 binding site) at 
concentrations of 1.0 µM or less [254, 255]. 15-dPGJ2 has also previously been 
described as an endogenous ligand of PPARγ, although this role is controversial 
because of the supraphysiological concentrations of 15d-PGJ2 required to 
activate this transcription factor. In vascular SMCs, the concentration of 15-
dPGJ2 required to increase expression of differentiation markers has been shown 
to be 10 µM or greater [95, 97-99, 256]. Therefore, since 15d-PGJ2 is more 
potent as an inhibitor of mPGES-1, as compared to an activator of PPARγ, lower 
concentrations of 15d-PGJ2 (0.1 µM, 1 µM, 2 µM) were primarily utilized to 
determine the effect of pharmacological inhibition of mPGES-1 in preventing 
hASMC de-differentiation.  
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15d-PGJ2 treatment under conditions of serum-deprivation resulted in 
significant increase (approximately 6-fold) in α-actin protein levels compared with 
vehicle-treated cells (Figure 7.3.3A). Treatment with 15d-PGJ2 under conditions 
of serum-stimulation, significantly reduced PGE2 concentrations (Figure 7.3.2B) 
and produced a trend toward an increase in α-actin levels (Figure 7.3.3B). Under 
conditions of re-stimulation, the extent of reduction of PGE2 synthesis was similar 
between the treatments using both concentrations of 15d-PGJ2 (0.1 µM and 1 
µM). The increase in α-actin levels under conditions of serum-deprivation far 
exceeded that observed under serum-stimulation. The presence of increased 
serum in media under conditions of serum-stimulation may have reduced the 
amounts of free 15d-PGJ2 within the cell media available for mPGES-1 inhibition 
due to increased protein binding under these conditions. Therefore, to account 
for this, cells were treated with 10 µM of 15d-PGJ2 under de-differentiation-
promoting media containing increased serum (5% FBS) and after 1 day of 
treatment, a 9-fold increase in α-actin expression in treated cells compared with 
vehicle-treated controls was observed (Figure 7.3.3C).   
To investigate if the effects of 15d-PGJ2 on increasing differentiation is 
due to PPARɣ activation and not mPGES-1 inhibition, cells were treated with 
Rosiglitazone, a well-established PPARɣ activator under conditions promoting 
either differentiation or de-differentiation. Treatment of these cells with 
Rosiglitazone did not increase α-actin levels in treated cells like that observed 
with 15d-PGJ2 treatment thus suggesting that 15d-PGJ2 is not inducing 
differentiation in these cells by acting through PPARɣ (Figure 7.3.3.1).  
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Although mPGES-1 is considered a valuable target for developing novel 
anti-inflammatory medications, few compounds have been identified with activity 
for inhibiting this enzyme. Although 15d-PGJ2 is a potent inhibitor of mPGES-1, 
the differentiation-promoting effects observed have the potential to occur through 
PPARγ-dependent mechanisms, rather than by inhibiting mPGES-1. Therefore, 
as an additional method to the pharmacological inhibition of mPGES-1, PGE2 
levels were reduced by transient knockdown of mPGES-1 mRNA expression and 
the effect on cell differentiation was examined. Even though PGE2 may be 
synthesized by 3 synthases, mPGES-1 was selected for targeting because the 
majority of the PGE2 formed in response to COX-2 induction is dependent on this 
enzyme [121, 122]. Successful siRNA knock-down of mPGES-1 with consequent 
reduction in PGE2 levels has previously been reported in different cell culture 
models including vascular SMCs [109, 246, 257]. Furthermore, deletion of 
mPGES-1 in vitro and in vivo has been shown to reduce PGE2 levels [107, 127]. 
Upon siRNA-mediated mPGES-1 transfection, there was significant reduction in 
mPGES-1 mRNA expression and protein levels, with concurrent reduction in 
PGE2 concentrations. In addition, the reduction in endogenous PGE2 production 
was associated with significant increase in mRNA and protein markers of 
differentiation, as well as significant reduction in expression of de-differentiation 
markers (section 7.3.4). These results are in agreement with results from 
pharmacological inhibition of mPGES-1 as well as exogenous PGE2 treatment. 
Therefore, these findings have demonstrated that PGE2 is a primary product of 
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COX-2 in hASMCs and that activation of the mPGES-1/PGE2 pathway is 
prominent mechanism contributing to hASMC de-differentiation.  
The expression of COX-2 has long been known to be regulated by 
products dependent on COX-2 activity for their synthesis. Feedback mechanisms 
have been shown to either increase or decrease COX-2 expression in a variety 
of cell types and PGE2 is the prostanoid most often implicated in affecting the 
expression of COX-2. In the regulation of cellular differentiation, a positive 
feedback mechanism for PGE2 induction of COX-2 functions to suppress the 
differentiation of monocytes into dendritic cells [241]. In the kidney of mice, a 
negative feedback mechanism occurs in which activation of EP3 receptors by the 
PGE2 analog, sulprostone, results in downregulation of COX-2 expression [242]. 
Similarly in arterial SMCs, the expression of COX-2 is strongly inhibited by 
treatment with exogenous PGE2, thereby indicating the presence of a negative 
feedback mechanism [243, 244]. In the current studies, the role of PGE2 in 
regulating the expression of COX-2 in these cells under different conditions was 
examined.  Under conditions of serum-deprivation in which low levels of COX-2 
are expressed, PGE2 treatment resulted in a dose- and time-dependent increase 
in COX-2 mRNA expression (7.4.1). Following the reduction in PGE2 resulting 
from siRNA-mediated mPGES-1 knockdown, the opposite effect was observed 
with significantly reduced COX-2 expression levels in siRNA-treated cells (7.4.2). 
These results indicate the presence of a positive feedback mechanism occurring 
with PGE2 increasing COX-2 expression in hASMCs.  
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Numerous reports describing the expression characteristics of mPGES-1 
have shown the synthase to be co-expressed and functionally coupled with COX-
2 in response to a range of extracellular and intracellular stimuli [17, 106, 108, 
111, 113, 117-120]. Furthermore, the majority of the PGE2 formed in response 
these various stimuli which induce COX-2, is dependent on the expression of 
mPGES-1 (10, 11, 52). In addition to these findings, other reports describe 
differences in expression between COX-2 and mPGES-1. In the murine 
mammary gland during lactogenic differentiation, mPGES-1 production of PGE2 
is dependent on the activity of COX-1 and not COX-2 [79]. In addition, in rat 
microglia cells, LPS-induced mPGES-1 synthesis was not coupled with 
corresponding increase in COX-2 levels [245]. Furthermore, in vascular SMCs, 
the time-course of IL-1β induced mPGES-1 expression and PGE2 synthesis was 
delayed compared with expression of COX-2, and depending on the time of 
incubation with IL-1β, either COX-1 or COX-2 could be involved in the synthesis 
of PGE2, thus demonstrating uncoupling of mPGES-1 expression with either 
COX-2 enzyme [246].  
In these studies, profound reduction in PGE2 synthesis in celecoxib-
treated cells was observed (7.3.2), as well as a significant increase in PGE2 
concentrations when cells were cultured under conditions shown to induce COX-
2 expression (serum-stimulation) (7.3.1). Therefore, it was expected of both 
COX-2 and mPGES-1 to demonstrate coupled expression in hASMCs. In 
contrast however, even though PGE2 treatment significantly induced COX-2 
mRNA expression, significant reduction in mPGES-1 mRNA expression following 
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PGE2 treatment. Therefore, our findings suggest that PGE2 may also promote de-
differentiation by potentiating the actions of COX-2 through a positive feedback 
mechanism, and unlike other studies showing similar expression patterns 
between COX-2 and mPGES-1, in hASMCs the regulation of expression of these 
two enzymes may occur different mechanisms.  
PGE2 activity is modulated via activation of four different G-protein-
coupled receptors known as EP1, EP2, EP3 and EP4. These four classes of 
receptors are structurally and functionally distinct, and their effects are mediated 
through different downstream signaling pathways (5, 14, 16, 45, 46). In addition 
to the four classes, the EP3 protein exists as 8 different forms that result from 
splice variants of the mRNA (86).  
In order to investigate the receptors responsible for PGE2's effect on 
reducing differentiation, a PGE2 analogue that is a selective agonist of the EP4 
receptor was utilized. CAY10580 shows approximately a 100-fold selectivity for 
the EP4 receptor over the other EP receptors and has a disassociation constant 
for EP4 of approximately 50 nM. To examine the effect of EP4-selective 
activation, the initial studies were performed under serum-free conditions to 
eliminate the potential for interaction with serum proteins. In order to maintain 
selectivity for activating the EP4 receptor, these studies utilized a CAY10580 
concentration of 0.1 µM, which is approximately twice the concentration of the 
disassociation constant. These studies also examined the effect of different 
durations of treatment and at different stages of the serum deprivation used to 
induce differentiation. However, neither treatment for 1 day or 2 days under these 
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varying conditions significantly reduced the protein expression of α-actin, SM22α 
or mPGES-1, as observed following treatment with PGE2 (7.6.1). In addition to 
the treatments in serum-free media, the effects of EP4-selective activation under 
conditions promoting differentiation was also examined. Because of the presence 
of serum in the differentiation-promoting media, a higher concentration of 0.3 µM 
of the EP4-selective agonist was utilized. In contrast to our findings using serum-
free media, the treatment of hASMCs with the EP4 receptor-selective agonist 
significantly reduced expression of α-actin, as determined by 
immunohistochemical quantitation (7.6.2). Therefore, although these findings 
suggest a role for the EP4 receptor in contributing to reduced differentiation 
under differentiation-promoting conditions, a role for this receptor being 
responsible for the potent de-differentiation effects of PGE2 on hASMCs that was 
observed under multiple culture conditions is not conclusive.  
In summary cultured human aortic smooth muscle cells (hASMCs) were 
utilized as an in vitro model to explore the role of components of the COX-
2/mPGES1/PGE2 axis on SMC phenotypic modulation to better understand the 
contribution of this to pathway to the alteration in differentiation observed with in 
vivo cardiovascular diseases such as AAAs. The reduced differentiation 
occurring in hASMCs may be mediated by the action of mPGES-1-derived PGE2. 
PGE2 added to the cell media exogenously will reduce differentiation and also 
prevent the induction of differentiation in quiescent cells. Furthermore, these 
findings demonstrate that inhibition of endogenous production of PGE2 via 
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pharmacological or siRNA inactivation of mPGES-1 reduces PGE2 production 
and promotes hASMC differentiation.  
With the involvement of PGE2 in the pathogenesis of numerous 
cardiovascular diseases including AAAs, the inhibition of mPGES-1 is expected 
to be an important future method of effectively reducing PGE2 synthesis, thereby 
preserving the differentiated phenotype. Therefore, pharmacological inhibition of 
mPGES-1 may provide a mechanism of inhibiting PGE2 synthesis that is more 
specific than celecoxib treatment, and may serve as a novel target for attenuating 
AAA progression by promoting and maintaining a differentiated SMC phenotype.  
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CHAPTER 8: EFFECTS OF OTHER PROSTANOIDS ON HUMAN AORTIC 
SMOOTH MUSCLE CELL PHENOTYPIC MODULATION 
Introduction 
Aside from the effects of PGE2 on the phenotype of vascular smooth 
muscle cells (SMCs), other prostanoids have been demonstrated in the literature 
to modulate the phenotype of vascular SMCs in a variety of physiological or 
pathological disease states. Prostacyclin (PGI2) and thromboxane (TXA2) are 
both prostanoids which have been demonstrated to produce opposing effects 
within the vasculature. Several studies have indicated that a balance between 
these prostanoids is important in the maintenance of the endothelial integrity of 
the vessels and overall vascular homeostasis [64, 88, 258].  
Prostacyclin is the primary COX-2 product in endothelial cells and the 
synthase downstream of COX-2 responsible for PGI2 production is also 
expressed in vascular SMCs and platelets [33]. PGI2 is a potent vasodilator and 
an inhibitor of platelet aggregation and thrombus formation [87, 259]. These 
effects have been demonstrated to be produced by activation of the prostacyclin 
receptor (IP) by PGI2 resulting in cAMP production and stimulation of 
downstream signaling cascades [260]. In addition to its role as a potent anti-
aggregatory [259, 261], anti-proliferative [262-265] and anti-migratory [266, 267] 
agent, prostacyclin and prostacyclin-mimetic agents have been also 
demonstrated to promote the contractile state by inducing the expression of 
markers of the differentiated phenotype in vascular SMCs [33, 92]. 
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Thromboxane (TXA2) on the other hand is primarily a derivative of COX-1-
catalyzed arachidonic acid metabolism which is released by activated platelets 
[268]. Contrary to PGI2, TXA2 is involved in promotion of platelet aggregation and 
vasoconstriction [77]. In addition, TXA2 and stable thromboxane-mimetics 
activate the thromboxane receptor (TP), stimulate DNA synthesis, and promote 
cell proliferation in vascular SMCs [265, 269, 270]. However, there is limited 
literature demonstrating the effects of TXA2 or TP receptor stimulation on 
vascular SMC phenotypic modulation.  
Therefore, the effects of IP and TP receptor stimulation on the 
differentiation state of human aortic smooth muscle cells (hASMCs) were 
examined. Using Iloprost, a specific agonist of the IP receptor, the effect of IP 
stimulation on hASMC differentiation was examined. For the TP receptor, a TP 
receptor agonist, IBOP, as well as 2 antagonists, SQ 29548 and seratrodast, to 
perturb the effects of these agents individually on the phenotype of these cells. 
 
Results 
8.1 Iloprost, a PGI2 mimetic agent promotes differentiation in hASMCs after 
1 day of treatment under de-differentiation-promoting conditions. 
To examine the effect of PGI2 on the phenotype of hASMCs, cells were 
cultured under conditions promoting differentiation for 2 days and then treated 
cells with iloprost under media conditions promoting either de-differentiation or 
differentiation for 1 or 2 days. Control cells were treated with vehicle (0.1% ethyl 
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acetate) in culture media. Cells were lysed, harvested and analyzed for α-actin 
protein expression via western blotting. Treatment of hASMCs with iloprost under 
conditions promoting de-differentiation resulted in a significant increase in α-actin 
protein levels at the 1 day time-point, as compared with vehicle-treated control, 
but not after 2 days of treatment (Figure 8.1A and B). In cells treated with Iloprost 
under conditions promoting differentiation, there was not a significant increase in 
α-actin protein expression, as compared to vehicle-treated cells (Figure 8.1C). 
Figure 8.1 Iloprost, a PGI2 mimetic agent promotes differentiation in 
hASMCs after 1 day of treatment under de-differentiation-promoting 
conditions.  
Representative western blot and densitometry quantitation of α-actin in 
differentiated cells treated with 1µM of iloprost under de-differentiation-promoting 
conditions for (A) 1 day or (B) 2 days; (C) treatment with 1 µM of iloprost under 
differentiation-promoting conditions for 1 day. Data represents mean + SEM (n ≥ 
3), p < 0.05, unpaired Student’s t-test. 
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After treatment of differentiated cells with IBOP under differentiation-
promoting conditions at both time points, a trend toward reduction in α-actin 
protein levels in treated cells compared with vehicle-treated cells was observed, 
but this decrease was not statistically significant (Figure 8.2 A & B). For 
differentiated cells treated with 5 µM IBOP under conditions promoting de-
differentiation, there was a reduction in α-actin protein levels at both time points 
compared with vehicle-treated controls at the 1 day time point (Figure 8.2 C) and 
the reduction was significant at the 2-day time point (Figure 8.2 D).  
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time points. Cells were lysed, harvested and examined for α-actin protein levels 
via western blotting.  
Cells treated for 1 day with either 50 or 300 nM SQ29548 demonstrated only 
a trend towards a reduction in actin levels, as compared with vehicle-treated 
controls (Figure 8.3A and B). This trend was reversed by the 2-day time point 
where there was a trend towards an increase in α-actin levels observed in treated 
cells at both concentrations, as compared with vehicle-treated controls (Figure 
8.3 C and D). However, neither of these effects was statistically significant.  
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and then treated with 1, 10 or 100 µM of seratrodast in differentiation-promoting 
media. Control cells were treated with vehicle (0.1% of DMSO) in appropriate 
media. After 1 day of incubation, cells were lysed, harvested and then analyzed 
for α-actin protein levels by western blotting.   
Treatment of cells under conditions promoting de-differentiation or 
differentiation did not significantly increase α-actin protein levels. A trend toward 
reduction in α-actin levels in cells treated with 100 µM seratrodast in de-
differentiation-promoting media was observed and this reduction was significant 
compared with vehicle-treated controls in 100 µM seratrodast-treated cells under 
differentiation-promoting conditions. 
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to having opposing effects on the vasculature, the synthesis of both prostanoids 
is also coupled to different COX isoforms with thromboxane A2 synthesis 
primarily coupled with COX-1 in platelets, and that of prostacyclin produced by 
endothelial cells resulting from the activity of COX-2 [219, 268, 272, 273]. Based 
on this coupling, it has been suggested that the increased risk of adverse 
cardiovascular events with the prolonged use of COX-2 inhibitors (such as 
celecoxib, rofecoxib and valdecoxib) may be due to the decrease in PGI2 
production without affecting TXA2 levels, thereby disrupting the homeostatic 
balance between both prostanoids [33, 258]. Thus, the hypothesis was proposed 
that prostacyclin may contribute to maintenance of cardiovascular homeostasis 
by promoting the differentiated phenotype while TXA2 would promote the de-
differentiated phenotype. 
In order to investigate the effects of prostacyclin (PGI2) on the SMC 
phenotype, the stable prostacyclin-mimetic iloprost was utilized to treat the cells 
under different conditions. Iloprost is a structural analog of prostacyclin (PGI2) 
which is more stable than prostacyclin and binds to the human recombinant IP 
receptors with a Ki of 11 nM [274]. In addition, iloprost has been approved for 
clinical use in the management of pulmonary arterial hypertension. Treatment of 
differentiated hASMCs with iloprost for 1 day under conditions promoting de-
differentiation showed a significant increase in α-actin protein levels, as 
compared with vehicle-treated controls (Figure 8.1). These results are similar to 
those reported by other researchers who have demonstrated that PGI2 mimetics 
promote the contractile state by inducing the expression of markers of the 
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differentiated phenotype in vascular SMCs [33, 92, 275]. Although the 
differentiation-promoting effects of PGI2 on SMCs may be expected to be 
beneficial in retarding the in vivo development of cardiovascular disease, the 
limited synthesis of PGI2 by vascular SMCs reduces the potential significance of 
PGI2 as an endogenous modulator of differentiation in our current culture model.  
Thromboxane A2 has been shown to promote proliferation [265, 269, 270] 
in vascular SMCs. However, though it was previously assumed that the 
processes of proliferation and differentiation were coupled, with reduction in 
proliferation being a prerequisite for differentiation, current findings have 
demonstrated that these processes are not mutually exclusive [88]. Therefore, 
since TXA2 promotes cell proliferation, it is not assumed that this product would 
also inhibit vascular SMC differentiation. To investigate the effect of thromboxane 
(TXA2) on the SMC phenotype, the effect of TXA2 receptor (TP) activation as well 
as antagonism in these cells was examined. IBOP, a TXA2 receptor agonist, 
produced an overall non-significant trend toward inducing de-differentiation in 
these SMCs by reducing expression of α-actin in differentiated cells under both 
conditions of differentiation and growth (Figure 8.2). Thromboxane has been 
shown to promote hypertrophy of vascular SMCs by upregulating the synthesis of 
basic fibroblast growth factor (FGF) endogenously, thereby inducing SMC 
proliferation [276]. A variety of growth factors (including FGF) in cell culture 
media have been shown to promote the de-differentiated state in cultured 
vascular SMCs [6, 167, 174]. Therefore, TXA2 may promote reduction in hASMC 
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differentiation by increasing the expression of growth-promoting factors produced 
by the cells.  
To further investigate the effects of thromboxane on hASMC phenotype, 
the effects of TP receptor antagonists on the expression of SMC differentiation 
markers in these hASMCs were examined. SQ29548 is potent TP receptor 
antagonist demonstrated to bind to the TP receptor with a ki of about 1.6 nM 
[277, 278]. hASMCs were treated with SQ29548 at concentrations exponentially 
higher than this (50 nM or 300 nM) in order to account for potential binding of this 
antagonist to proteins in the serum of the media. Contrasting effects of SQ 29548 
were observed treatment in these cells, with treatment for 1 day showing a trend 
toward reduction in α-actin protein levels whereas, at the 2 day time point, 
treatment with SQ29548 at 50 and 300 nM produced a non-significant trend 
toward an increase in α-actin expression. The current studies also utilized the TP 
receptor antagonist, seratrodast. Despite treating cells with varying 
concentrations of seratrodast, there was no observed increase in α-actin protein 
expression, and the highest concentration of seratrodast (100 µM) decreased 
expression, likely the result of non-specific binding. Although TXA2 release has 
been reported to be coupled with COX-1 in platelets, recent results have shown 
that serum-stimulation increases COX-2 expression and this is associated with 
TXA2 release from the vascular SMCs. In vascular SMCs obtained from the type 
2 diabetic mouse model (db/db mice), TP receptor antagonism by SQ29548 was 
demonstrated to reduce COX-2-dependent vascular smooth muscle hyper-
reactivity mediated by endogenous TXA2 [279]. Similarly, in another model, IL-1β 
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stimulation induced COX-2 expression thereby increasing the production of TXA2 
in vascular SMCs [81]. Therefore, although increased synthesis of TXA2 that 
results from an induction of COX-2 expression has been shown to occur in other 
SMC culture models, these current studies suggest that there is limited 
importance for a role of TXA2 as an endogenous regulator of hASMC 
differentiation.  
Despite a thorough search of the literature, there are no reported studies 
indicating the effects of TXA2 receptor activation or antagonism on the vascular 
SMC phenotype. This may be due to the fact that most of the focus has been on 
the detrimental pro-thrombotic, platelet aggregatory, and vasoconstriction effects 
of this prostanoid within the vasculature, since thrombus-formation and 
vasoconstriction induced by TXA2 are implicated in the incidence of myocardial 
infarction, hypertension, and stroke. Even though there is a trend towards 
reduction in differentiation with IBOP treatment in these hASMCs, the 
concentrations of IBOP utilized are much greater than the EC50 of IBOP (about 2 
nM) reported in the literature and thus may not be physiologically relevant [280]. 
Therefore, it is difficult to ascertain how much, and to what extent the reduction in 
α-actin protein levels may be attributed to the action of IBOP activating the TP 
receptor or other off-target effects. Furthermore, studies have reported that 
stimulation of COX-2 in vascular SMCs promotes endogenous release of TXA2 
[81, 279]. Since the level of this prostanoid was not measured in these studies, 
the effect of the presence/absence of endogenous levels of TXA2 in the cells with 
respect to modulation of the hASMC phenotype is unknown. Even though there 
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was an observed increase in α-actin protein levels in cells treated with the TP 
receptor antagonist, SQ29548, this effect was not consistent and treatment with 
Seratrodast did not induce differentiation in these cells. Therefore, to better 
understand the role of TXA2 in hASMC phenotypic modulation, future studies 
would need to examine the endogenous production of this prostanoid as well as 
TXA2 synthase expression and their correlation with the differentiation state of 
the cell.  
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